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Abstract
Development of new polymer structures for local drug delivery to the brain is an exciting
research area. The main aim of this study is to develop biocompatible controlled drug
delivery systems, using biodegradable or conducting polymers, for the treatment of central
nervous system disorders such as epilepsy.

Epilepsy affects 1% of the global population and is drug-resistant in more than 30% of cases.
The reasons for this are still not well understood. However, there is a significant body of
evidence pointing to the blood-brain barrier. Resective surgery can provide an alternative
method of epilepsy control; however, this treatment option is not suitable for most epilepsy
sufferers. To improve the therapeutic efficacy of epilepsy medication, a promising approach
is to deliver anti-epilepsy drugs directly to affected brain areas using appropriately designed
implantable local drug delivery systems, therefore avoiding the blood-brain barrier. The drug
delivery systems must meet some criteria, including high drug encapsulation efficiency,
biodegradability, neuro-cytocompatibility and predictability of drug release profiles. Here,
Chapter 3 investigates the development of fibre- and sphere-based microcapsules that exhibit
controllable and uniform morphologies and drug release profiles as predicted by
mathematical modelling. Importantly, both forms of fabricated microcapsules are compatible
with human brain-derived neural stem cells and their differentiation to neurons and
supporting neuroglia, indicating clinical compliance for neural transplantation and therapeutic
drug delivery.

vii

After that, to develop effective local delivery systems with longer release periods and more
diverse release profiles, preparation of a variety of core-shell microcapsules via novel coreshell electrojetting, where a more hydrophobic polymer shell acts as a physical barrier to
control the rate of drug release from the drug-loaded polymeric core, was considered in
Chapter 4. The resulting microcapsules demonstrated high drug encapsulation efficiency,
narrow size distribution and uniform morphology. Moreover, the release rate of drugs can be
modulated by controlling the morphologies of the core-shell microcapsules.

Combination therapy involving more than one medication has shown promise in the
treatment of a number of diseases. A key challenge is to concurrently ensure effective doses
for each medication. Therefore, there is an urgent need for developing dual or multi-drug
delivery systems to attain sustained and predictable release profiles for individual drugs.
Chapter 5 presents a simple and versatile approach to developing dual drug delivery systems.
Both electrospinning and electrospraying were employed to fabricate composite membranes
that were composed of microfibrous matrices interspersed with microspheres. Two different
composite membranes were fabricated including PLA phenytoin fibre/ PLGA lacosamide
sphere composite membranes and PLA lacosamide fibre/ PLGA dexamethasone sphere
composite membranes, respectively.

The resultant composite membranes exhibited

favourable thermal and mechanical properties. In contrast to loading dual or multiple drugs
into the same micro- or nano- structure, these dual microstructural composite membranes
show not only controllable dosage but also different release rates for each drug
independently. Moreover, the release profile of each drug can be predictable using
mathematical modelling.

viii

On-demand drug delivery is becoming feasible through the application of appropriate stimuliresponsive materials. In addition to the above passive drug delivery systems, we have also
developed 3D electrically responsive system for programmed drug delivery in Chapter 6. 3D
printed (selective laser melting) interdigitated Ti6Al4V electrodes were used for
electrodeposition of conductive polymer coatings (polypyrrole) doped with an anti-epilepsy
prodrug, fosphenytoin. We have shown that drug release from the 3D conductive electrodes
is precisely controlled by biphasic electrical stimulation. Moreover, dual drug delivery is
achieved by further coating of the 3D electrodes with dexamethasone-loaded biodegradable
microspheres. The interdigitated electrodes can be served as multi-function drug delivery
systems. These 3D printed electrodes represent a novel electrically on-demand drug delivery
system for treatment of central nervous system diseases including epilepsy.

Chapter 7 gives the main research conclusion and the prospect of further research work.
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1. CHAPTER 1: GENERAL
INTRODUCTION
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1.1 Drug delivery general introduction
Advanced systems for drug delivery have attracted tremendous interest recently, in particular
in the field of developing technologies concerning drug formulation, route of administration,
site targeting, metabolism, and toxicity [1-12]. These technologies aim to deliver
pharmaceutical agents to the site of action in order to maximize the therapeutic effect,
minimize side effects, and enhance patient compliance. Unfortunately, there are two types of
barriers to these delivery processes; (i) the complexity of the paths to reach the target disease
site, and (ii) the limitation of tools to control the delivery behaviour [6, 13]. When the
administered drug (free without a carrier) arrives into the human bloodstream, it will undergo
various metabolic processes, such as renal clearance and distribution in non-target tissues
[14]. Usually, these metabolic processes reduce the drug concentration and therapeutic effect
at target tissues and increase the toxic side effects. However, due to the development of
materials science and pharmaceutics, a wide range of carriers with multiple functions, diverse
architectures, and special surface properties have been investigated [11, 15, 16].

1.1.1 Oral drug delivery
The most favourable drug administration is oral dosage, near 80% of the worldwide market
[17]. It is patient friendly, non-painful, and convenient for self-medication. Compared to the
administration via injection (subcutaneous, intramuscular, and intravenous delivery, etc.),
oral delivery reduces the risk of disease transmission, cost, while increasing patient
compliance. However, with the development of new therapeutics, more and more
biotechnology-based drugs such as peptides, proteins, and other macromolecular drugs have
been very effective in treating various diseases. Because of their structures, effective
administration by oral route presents a significant challenge [18, 19].
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Loaded nanocarriers
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Figure 1.1 The possible obstacles for oral delivery of biological therapeutics. Reproduced
from reference [20].

Due to gastrointestinal barriers (Figure 1.1), these biological therapeutics have poor oral
bioavailability and are rarely used for direct oral administration [20, 21]. Therefore, it is
necessary to design effective drug delivery systems in order to improve their bioavailability.
Tremendous attempts have been made to overcome the challenges presented by the
gastrointestinal barriers for oral delivery of therapeutic peptides and proteins, among which
novel nanocarriers have shown their potential for improved oral administration [20]. The
nanocarriers

include

nanoemulsions,

dendrimers,

micelles,

liposomes,

solid

lipid

nanoparticles and biodegradable polymeric nanoparticles [22]. However, each type of the
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nanocarriers has their own limitations, and much work still needs to be done in order to gain
wide clinical acceptance [23].

1.1.2 Transdermal drug delivery
Transdermal drug delivery has attracted tremendous interest and provides an attractive
alternative to oral delivery and hypodermic injections [3, 24]. Besides being non-invasive and
easily self-administered, in some cases, it can improve patient compliance and provide a
release for long periods of time. Compared with oral administration, transdermal delivery has
a particular advantage which can avoid the first-pass effect of the liver that can prematurely
metabolize drugs [25]. Transdermal delivery also has advantages compared with hypodermic
injection, which is painful and generates dangerous medical waste. Additionally, transdermal
delivery systems are generally inexpensive compared to hypodermic injections, and would
be only slightly more expensive than a tablet.

The first systemic transdermal delivery was approved by the Food and Drug Administration
(FDA) in 1979 and used for motion sickness treatment. Until now, more than one billion
transdermal patches are produced every year. However, only a limited number of drugs are
amenable to administration by transdermal delivery, which is one of the greatest challenges
for this administration method [24]. This limitation is ascribed to the inherent skin barrier
function. Skin is the largest organ of the human body with a very low permeability for
foreign molecules. As shown in Figure 1.2, the outmost layer is the stratum corneum. There
are tremendous lipids organized in bilayer structures between corneocytes which provide a
primary barrier to drug molecular penetration. The middle layer is viable epidermis. It
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possesses the function for stratum corneum continuous renewing. The inner fibrous layer is
the dermis, which provides the mechanical support for the skin [26].

Stratum corneum

Viable epidermis

Dermis

Stratum corneum

Viable epidermis

Dermis

Figure 1.2 Histological structure of human skin. Reproduced from reference [24].

Transdermal delivery systems can be divided into three generations:


1st generation consists mostly of the patches produced today. The therapeutics in these
patches can cross the skin but with little or no enhancement in penetration rate. For
example, the nicotine patches had helped smokers and increased their lifespan [27].
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2nd generation of transdermal delivery systems have been developed for delivery of
small molecules with enhanced skin permeability and driving forces.



3rd generation of transdermal delivery systems enable transdermal delivery of not only
small molecule drugs, but also biological macromolecules, such as virus-based and
other vaccines et al. This generation enables stronger disruption of the stratum
corneum barrier, and is thereby a most effective transdermal delivery system [28].
However, the third generation of transdermal delivery systems are still at an early
developmental stage.

1.1.3 Local drug delivery
In systemic drug delivery, the drug enters into the blood circulation system where the
concentration can quickly drop below an effective level. In addition, too much drug
distributes to non-target tissues with only a small portion of the drug reaching the target site.
To increase the dosage to the target tissues in these situations, re-administration is required,
which unfortunately leads to an increased risk of overdose and the possibility of serious side
effects [29].

Local drug delivery, also known as regional drug delivery, is an approach which has been
developed to improve the selectivity of therapeutic reagents for target tissues. Compared with
the systemic drug delivery routes, local delivery could significantly increase the drug
concentrations at the disease site, thereby reducing drug loading dosage required since it is
effective at avoiding the anatomic or physiological barriers, which lead to rapid drug
elimination during the systemic circulation or in non-target tissue [30]. As shown in Figure
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1.3, one of a most typical example of local drug delivery study is implanting these delivery
systems next to tumours for continuously long period release [31].

a

a

b
b
c

d
e

c
d
e

Figure 1.3 Local drug delivery strategies for cancer treatment, including a) wafers in the
brain, b) film in the lung, c) rod in the liver, d) gel in the intestine or stomach, d)
nanoparticles in the ootheca. Reproduced from reference [31].

1.1.4 Targeted drug delivery
The concept of targeted drug delivery was first proposed by Ehrlich at the beginning of the
last century [32]. Until recent decades, targeted drug delivery has been approaching the
forefront of biomedical research [33-38]. By combination of therapeutic reagents with a
smart carrier, targeted drug delivery systems can be selectively accumulated in targeted cell,
tissue, and organ. Because of the concentration of drugs in target sites, it can significantly
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reduce the frequency of the dosage taken, fluctuation in circulating drug levels, and side
effects associated with drug toxicity in non-targeted areas [34].

1.1.4.1 Kinds of targeting strategies
There are two kinds of strategies used for the targeted delivery of polymer encapsulated drug
to cancerous tissue: passive targeting and active targeting [39]. Passive targeting relies on the
Enhanced Permeation and Retention (EPR) effect. As a result, the concentration of the drug
delivery systems in tumour tissue can be much higher than those in normal tissue (Figure
1.4).
Normal tissue pH 7.4

Nanocarriers with
drugs
Free drugs

Tumor tissue pH <6.5

Figure 1.4 Schematic illustrations of passive targeting delivery compared with free drugs
without a carrier. Reproduced from reference [40].
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However, due to the presence of various biological barriers in the human body, the actual
concentration of a drug at the tumour site can be low, yielding a low therapeutic efficacy
[41]. Different from passive targeting, active targeting conjugates target molecules on the
surface of polymer encapsulated drug particle (Figure 1.5). It can recognize and bind to
specific ligands on the cancer cells [39]. This approach significantly increases the drug
concentration in the tumour site by both local and systemic administration.

Drug loaded
nanocarriers

Folate-modification

Tumor cell

Folate receptors

Receptor modified
endocytosis

Released drug
Nucleus

Figure 1.5 Schematic illustration of active targeting delivery, using folate modified
nanocarrier as an example, receptor mediated. Reproduced from reference [40].
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1.1.4.2 Application in cancer therapy
Cancer therapy is one of the most important applications of targeted drug delivery [37].
Cancer is a group of diseases involving abnormal cell growth, which causes nearly 14.6% of
human deaths each year [42]. It was considered incurable, but most patients diagnosed and
treated at an early stage will survive today. There are over 100 known cancers that affect
humans, for most of them; chemotherapy has become an integral component of cancer
treatment. However, chemotherapeutic agents typically have poor specificity in reaching
tumour tissue and are often restricted by dose-limiting toxicity. Development of proper target
polymer encapsulation drug delivery can provide a more efficient and less harmful solution to
overcome the limitations.

1.1.4.3 Application in brain-related diseases
Another interesting and important application of targeted drug delivery is the development of
nanoparticles for delivery of drugs to brain-related diseases [43-45]. Compared with delivery
targeting to other organs, drug delivery to the brain is more challenging; since drugs have to
cross the blood brain barrier (BBB) before reaching the targets. The BBB serves to restrict
the movement of substances between the CNS and the blood circulation. It is formed
primarily by endothelial cells which form complex, tight junctions (Figure 1.6) with
substantial transendothelial electrical resistance, creating a physical barrier that severely
limits paracellular transport across the BBB [43].
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Figure 1.6 The blood-brain barrier (BBB) is mainly composed of vascular endothelial cells,
highly connected by adherens and tight junctions, and a sparse layer of pericytes. Reproduced
from reference [45].

In order to deliver the drugs to the brain, tremendous efforts have been made to develop
nanoparticle-based targeted drug delivery for systemic delivery of therapeutic reagent [4547]. Usually, the nanoparticle-based targeted drug delivery surface is modified to specifically
recognize and bind exclusively to the surface of diseased cells [47]. The nanoparticle-based
targeted drug delivery systems include polymer nanoparticles and micelles, liposomes,
nanoscale ceramics, and nanoscale carbon et al. This nanoscale targeted drug delivery has
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been designed to improve delivery efficiency, drug nanomedicine, and to reduce off-target
effects of drug payload.

1.2 Polymer for drug delivery
Spurred by progress in materials science and fabrication techniques, a wide range of materials
have been applied in drug delivery as carriers. Among them, polymers are one of the most
commonly used materials [48-53]. Due to their diversity in chemistry, architecture, and
dimension, polymer materials can meet the increasing requirements of developing new drug
delivery systems [54]. Most of the well-developed polymeric carriers are compatible with the
drug to form stable delivery systems during synthesis, storage, and administration process.

The first investigation of controlled release from polymers was conducted by Folkman and
Long in 1964 using silicone rubber [55]. Later, in the 1970s, the biodegradable polymers
were applied as drug delivery materials [56]. At that time, the concept of “drug delivery” is
limited to achieving sustained long period of the releasing time. Today, after nearly half a
century of development drug delivery systems possess more smart release behaviours and
diversity in functions. During this time, a large number of polymers including different kinds
of natural, semi-natural, and synthetic polymers have been investigated. And several
polymer-based drug delivery systems have been “Regulatory Approved,” reaching the market
[57]. There are several important characteristics of polymeric carriers such as molecular
weight and its distribution, shape (architecture), size, and surface properties including
hydrophobicity, hydrophilicity, and charge density. Considerations of these important
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characteristics, the biodegradable polymer and conducting polymer have received tremendous
interest in drug delivery research.

1.2.1 Biodegradable polymer
The polymers used for therapeutic applications can be divided into two main classes:
biostable polymers and biodegradable polymers [58]. Biostable polymers have been used for
a long time both for permanently and temporarily in drug delivery. However, soon after they
emerged, biodegradable polymers have received great interest for temporary therapeutic
applications [59-63].

Prior to the Second International Scientific Workshop on Biodegradable Polymers and
Plastics at Montpellier, France, there were many definitions of the term “biodegradable
polymers.” It was at this workshop that a unified definition of the degradable polymer was
established as “a polymer in which the degradation is mediated at least partially by a
biological system.” According to resources, the biodegradable polymers can be either natural
or synthetic. No matter natural or synthetic, the desirable characteristics of polymer carriers
are biocompatible with the human body, nontoxic, and biodegradable [64-66]. Application of
natural biodegradable polymers for drug delivery is still attracting research since these
polymers are naturally available, relatively inexpensive. However, for the selection of a
biodegradable polymer carrier, there is a criterion that the mechanical properties and the
degradable rate should match to the needs of the clinical application [67]. Therefore, the
synthetic biodegradable polymers have their own advantage from these perspectives.
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1.2.1.1 Biodegradable polyesters
Table 1.1 Examples of commonly used biodegradable aliphatic polyesters and their thermal,
mechanical, biodegradable properties.
Polymer

Tm (oC)

Tg (oC)

Tensile modulus

Degradation time

(MPa)

(Months)

poly(glycolic acid)

225-230

35-40

7

6-12

L- poly(lactic acid)

173-178

60-65

2.7

>24

DL-poly(lactic acid)

Amorphous

55-60

1.9

12-16

poly(ε-caprolactone)

58-63

-65--60

0.4

>24

poly(lactic-co-glycolic acid)

Amorphous

50-55

2.0

5-6

(85/15)

The most widely investigated synthetic biodegradable polymers used in biomedicine for drug
delivery are aliphatic polyesters such as poly(glycolic acid) (PGA), poly(lactic acid),
poly(lactic-co-glycolic acid) (PLGA) and poly(ε-caprolactone) (PCL) respectively; as shown
in Table 1.1 and Figure 1.7 [65].
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a

b

c

d

Figure 1.7 Most commonly used biodegradable polyesters. a) L- and DL-PLA, b) PGA, c)
PLGA, d) PCL.

These aliphatic polyesters are derived from the lactic and glycolic acids monomers.
Compared to some natural biodegradable polymers (such as collagen, gelatin, chitosan, and
alginate), these synthetic biodegradable polymers are commercially available in different
compositions and molecular weights, and which allow control of degradation rate of the
polymers. Those early investigations demonstrated the well biocompatible, nontoxic, and
predictable properties of these aliphatic polyesters [68-70].
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1.2.1.2 Erosion and drug release mechanisms

Surface erosion

Bulk erosion

Degree
degradation

time

Figure 1.8 The schematic illustration of erosion mechanisms: surface erosion (left) and bulk
erosion (right). Reproduced from reference [71].
The aforesaid polyesters are generally prepared by ring-opening polymerization of the cyclic
esters. The degradation describes the process of polymer chain cleavage, leading to molecular
weight loss. And the degradation results in the subsequent erosion of the polymer. For the
biodegradable polymers, there are two kinds of erosion mechanisms: bulk erosion and surface
erosion [71]. Bulk erosion is also known as homogeneous erosion; surface erosion is also
known as heterogeneous erosion (as shown in Figure 1.8). Due to water penetration into the
polymer bulk being faster than polymer degradation, bulk erosion occurs all over the polymer
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cross-section. In contrast, for surface erosion biodegradable polymer, the degradation is faster
than the penetration of water into the bulk. However, for most biodegradable polymers, both
of these two mechanisms would occur with the erosion mechanisms having consequences on
the drug release mechanisms.

The drug release mechanisms from these biodegradable polymer matrices can be divided into
three kinds: (i) diffusion controlled, (ii) swelling controlled, and (iii) erosion controlled
(Figure 1.9). Degradation of the polyesters starts with the hydrolytic breakage of the ester
bonds. It occurs randomly via hydrolytic ester cleavage when water penetration into the
polymers leads to the subsequent erosion. Many parameters affect the degradation rate;
including molecular weight, polydispersity and crystallinity, polymer composition, and all
these factors can be used to control drug release [72]. For example, the copolymer PLGA,
which is a copolymer consisting of lactic acid and glycolic acid, the rate of degradation
increases with the ratio of glycolic acid to lactic acid. As an exception to this rule, when the
ratio of lactic acid and glycolic acid is 50/50, the rate of degradation is the fastest,
approximately two months in vivo [73].
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Diffusion process
Figure 1.9 Mechanism of drug release from degradable polymers. Reproduced from
reference [74].

1.2.1.3 Application in drug delivery
Recently, a wealth of studies has been conducted using PLGA, PLA as carriers for drug
delivery. In order to efficiently transport to the central nervous system through the bloodbrain barrier, Fornaguera et al. used nano-emulsion with a low-energy method to fabricate
loperamide loaded PLGA nanoparticles (as shown in Figure 1.10) [75]. Firstly, non-loaded
polymeric O/W (Oil phase/Water phase) nanoemulsion was prepared. Then, the emulsions
with 90 wt% of aqueous phase content and 70/30 O/W ratio was selected as a compromise
between 50 nm droplet and low surfactant contents. After that, the nano-emulsions were
18

reformulated containing 0.1 wt% drug in the oil phase and the droplet size around 100 nm.
Then, the drug-loaded PLGA nanoparticles were finally obtained by solvent evaporation.
This is a methodology which can be easily applied to the scalable production of nanoparticles
of biodegradable polymers (PLGA).

Figure 1.10 Schematic illustration of the fabrication and function of the loperamide loaded
PLGA nanoparticles. Reproduced from reference [75].

Ye et al. developed biodegradable polymeric vesicles as a nanocarrier system both for
multimodal bioimaging and anticancer drug delivery [76]. They synthesized PLGA-SPIONMn:ZnS vesicles as a multifunctional drug delivery system. It used the biodegradable
polymer as a shell containing multiple imaging agents and anti-cancer drug (Figure 1.11).
This drug delivery system showed enhanced imaging contrast, improved cell uptake, and
enhanced fluorescence visualization. It also exhibited both high entrapment efficiency for the
lipophilic drug busulfan and sustained drug release. The in vivo results confirmed the
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biodistribution to different tissues. Wan et al. developed PLGA microparticles by using the
spray-drying method. They used different molecular weight PLGA and different solvent
mixtures, which resulted in different drug diffusion rates during the process of microparticle
formation and the drug release profiles were dependent on the solvent composition.

Figure 1.11 Schematic illustration of the composition of PLGA composite nanoparticles and
their applications. Cited from reference [76].

Combining different biodegradable polymers or other polymers together to form a composite
carrier is also an attractive research area. PLGA nanoparticle was coated with a layer of
polydopamine. Then a layer of poly(ethylene glycol) was formed and the drug loading
content achieved a 3.8-fold increase [77]. Covalent surface modified PLGA microparticle
demonstrated enhanced durable binding on targeted cells and ultra-high cytostatic efficacy
20

[78]. Chitosan was also used to modify PLGA nanoparticles, and it showed a positive charge
surface and affected the drug release profile [79]. Other interesting work is that of the
fabrication of a hybrid dendrimer hydrogel/PLGA nanoparticle which can enhance drug
bioavailability, reduce dosing frequency, and substantially enhance sustaining drug activity
[80].

1.2.2 Conducting polymers
Conducting polymers can be categorized as intrinsic conducting polymers or composite
conducting polymers [81]. Here the focus is on intrinsic conducting polymers. Conductive
polymers are organic polymers with metallic electrical properties [82]. The first conducting
polymer, polyacetylene (PAc) was discovered in 1977 at Tokyo Institute of Technology by
Shirakawa et al. [83]. Until now, after several decades investigation and development, a
series of conducting polymers have found use in a wide range of applications both in research
and industry [84-90]. The most widely applied conducting polymers are polypyrrole (PPy)
[91, 92], polyaniline (PANi) [93, 94], polythiophene (PT) [95], and poly(3’4ethylenedioxythiophene) (PEDOT) [96, 97] (Table 1.2).
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Table 1.2 Typical conducting polymers and their structures.
Name

Molecular structure

polyacetylene (PAC)

polypyrrole (PPy)

polyaniline (PANi)

polythiophene (PT)

poly(3’4-ethylenedioxythiophene)
(PEDOT)

1.2.2.1 Synthesis of conducting polymer
Conducting polymers can be synthesized by chemical or electrochemical means, and involves
oxidative polymerization [82, 98]. Usually, the conducting polymers used for drug delivery
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are synthesised by using electrochemical oxidation. Compared to chemical polymerization,
the electrochemical polymerization process can be easily controlled by adjusting the amount,
and rate of charge passed during growth. Even the morphology and electromechanical
properties can be controlled [99].

The electrochemical oxidation in conducting polymer preparation process is usually carried
out using two-electrode or three-electrode systems with a reference electrode, a counter
electrode, and a working electrode [100]. The reference electrode is often silver/silver
chloride (Ag/AgCl), the counter electrode usually is platinum, and the conducting polymer is
deposited on the surface of the working electrode. Synthesis can be performed using either
constant potential, constant current or cyclic voltammetry which is referred to as
potentiostatic mode, galvanostatic mode, and potentiodynamic mode respectively.
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A-

Figure 1.12 The principle of electropolymerization of polypyrrole: the monomer is pyrrole,
A- is negative drug molecule, e-is electronic charge. Cited from reference [101].

Many parameters affect the final conducting polymer properties. However, the key process is
related to doping which incorporates anionic molecules into the polymer backbone [102].
Take polypyrrole preparation for example, where the dopant is A- (inserted into polypyrrole
backbone to alter the electrical characteristic), the pyrrole monomers would be
electrochemically oxidized and polymerized on the surface of the working electrode. At the
initiation, pyrrole monomers are oxidised to radical cations. Then the radical cations dimerise
24

with radical-radical coupling at α positions. The neutral dimer can then be oxidised to a
radical and later react with a monomer, dimer or oligomeric radical to grow the chain (as
shown in Figure 1.12) [101, 103].

1.2.2.2 Properties of conducting polymer
The inherent conductivity is attributable to the uninterrupted and ordered π-conjugated
structure of the polymer backbone (Table 1.2) [104]. The contiguous sp2 hybridized carbon
centres have high mobility when the polymers are doped by oxidation, which is responsible
for the electrical conductivity of the polymers. There is a one-dimensional electronic band
within the conducting polymers, and the electrons within this band would become mobile
electrons when holes are formed (empty of electron). The free electrons move along the
polymer backbone and result in the conductivity of the polymers (Figure 1.13). The degree
of conductivity depends on the electrons density and mobility, which can span several orders
of magnitude [105].
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Figure 1.13 Schematic illustrations of the conduction process in polypyrrole.
The mechanical properties of most conducting polymers are poor. They are brittle and easily
destroyed. The processability of conducting polymers is also poor. Most of them are not
soluble in common solvents, and cannot be melt processed. However, some polymers such as
polypyrrole and poly(3’4-ethylenedioxythiophene) have good biocompatibility and have been
widely applied in biomedical areas. Studies have shown that bioactive molecules can be
incorporated into the conducting polymers to enhance their biocompatibility [106, 107].
Moreover, the cellular reactions associated with implanted devices can be modulated by
stimulation via the conducting polymer [108].

1.2.2.3 Application in drug delivery
In drug delivery applications, negatively charged drugs or biomolecules have been
incorporated into conductive polymers such as Polypyrrole or PEDOT, during the process of
oxidative polymerization to maintain charge neutrality.
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Figure 1.14 The drug release from conducting polymer in response to electrical stimulation.

The electrically triggered release involves a synergistic process of electrochemical
reduction/oxidation and electrically driven movement of these charged molecules (dopant). In
drug delivery studies, charged drugs or biomolecules could be incorporated into the PPy
coating [109, 110]. When the PPy coating is electrochemically reduced, the doped molecules
will be released (Figure 1.14). The release of the drug is associated with the change of the
overall net charge along the PPy backbone in the oxidized form.
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Many parameters affect the amount of drug released and the release rate from conducting
polymers. As mentioned above, the conducting polymers for drug delivery applications are
usually deposited on the electrode as a film. Therefore, the total amount of the incorporated
drugs is related to the film thickness and density. Increasing the thickness and density will
lead to increased drug loading. However, the available drug for releasing is not linearly
increased with the thickness of the film. The thinner film could release a higher percentage of
the incorporated drugs [111, 112]. Actually, the releasing amount from conducting polymer is
a surface area dependent process, with drug releasing more efficiently from the surface than
the bulk of the film [113].

It has been demonstrated that the media used for release studies, with variations of pH, ionic
strength, influence the release profile from a conductive polymer [114]. However, electrical
stimulation parameters are key determining factors, affecting both the release amount and
release rate [115]. Potential sweeping has been used to release the drugs [116, 117]. Another
frequently applied electrical stimulation waveform is pulsed potential which changes the
potential instantaneously between set potentials [118, 119]. In addition, there is a clinical
stimulation to stimulate the conducting polymers by using a biphasic, charge balanced, and
high frequency current stimulation [120].

1.3 Technology in drug delivery
To overcome the problems raised by present drug administration, advanced nanotechnology
for fabricating nano- and micro-scale drug delivery systems has gained tremendous attention
[39, 121-129]. Compared with conventional technology, nanotechnology may revolutionise
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the rules and possibilities of drug discovery and change the landscape of pharmaceutical
industries [121, 130-133]. By application of nanotechnology to fabricate proper drug delivery
systems, it is possible to achieve improvement of pharmacokinetics and pharmacodynamics
including but not limited to the following aspects: (1) delivery of poor water soluble or very
short circulating half-life drugs which demonstrates potent biological activity; (2) passive
targeting or active targeting delivery of drugs to specific tissue or even into the single cell; (3)
transcytosis of drugs across special biological barriers such as skin or blood brain barrier; (4)
for combination therapy involving co-delivery of dual or multiple drugs; (5) delivery of
macromolecular drugs to intracellular sites of action; (6) for other biological applications to
deliver diagnostic or visualisation agent et al.

Liposomes are the first nanotechnology drug delivery system developed in the 1960s [134].
While the first controlled release polymer system for delivery of macromolecules was
reported in 1976 [135]. The first long circulating liposomes were described in 1987, and the
concept was later named “stealth liposomes” [136]. After that, the use of polyethylene glycol
(PEG) and polyesters such as PLA and PLGA was increased in the 1990s. A variety of
nanotechnology fabricated nanomaterials and devices for drug delivery systems were
developed (Figure 1.15).
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Figure 1.15 Timeline of nanotechnology-based drug delivery. Highlights of some delivery
systems that serve as important milestones throughout the history of drug delivery. Cited
from reference [130].

Among them, more than two dozen therapeutic delivery systems have been approved for
clinical use. Most of the clinical use delivery systems can be divided into either liposomal
drugs or polymer-drug conjugates [137]. In the future, it is important to continue using
nanotechnology to develop entirely new therapeutics delivery systems which differ from
these two kinds [130, 138].
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Figure 1.16 Nanotechnology-based synthetic methods: top-down or bottom-up engineering
of individual components.

Nanotechnology-based synthetic methods are most commonly developed on the basis of two
rational designs: either top-down or bottom-up engineering of individual components [122,
139]. The top-down process involves starting with a larger object and breaking it up into
nanostructures, whiles the bottom-up technique refers to synthesis based on atom-by-atom or
molecule-by-molecule arrangement in a controlled manner, which is usually regulated by
thermodynamic means (as demonstrated in Figure 1.16). There are many nanotechnology
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methods for fabricating drug delivery systems. Here, the focus is on technologies for
fabricating nano- or micro-scale polymeric fibres and particles including electrospinning and
electrospraying which are extensively used in this thesis.

1.3.1 Electrospinning
Electrospinning is a simple and effective method to fabricate polymer fibres with diameters
ranging from several nanometres to tens of micrometres [140-146]. The simple procedure,
possible large-scale production, and wide variety of suitable polymer materials, make
electrospinning an attractive technique for biomedical applications such as tissue engineering,
wound repairing, and drug delivery.

1.3.1.1 Electrospinning history
The term “electrospinning” is derived from electrostatic spinning, which has been extensively
used since the 1990s [140, 147]. However, the application of electrostatic forces to fabricate
fibres can be traced back more than two centuries. In 1745, Bose first demonstrated the use of
high electric potentials to fabricate aerosols. In 1882, Lord Rayleigh conducted an in-depth
investigation and calculated the charges number that was required to overcome the surface
tension of a droplet [148]. At the beginning of the last century, Cooley and Morton developed
the first device which can use an electrical charge to spray liquids. From 1934 to 1944, Anton
Formhals described the first experimental setup to use electrostatic forces to generate
polymeric fibres [149]. Cellulose acetate fibres with small diameters were firstly successfully
prepared. Formhals also had a patent for fabrication of composites fibres at that time [150].
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After Formhals, more works have been reported focusing on the better understanding of the
process of electrospinning. In 1969, Taylor investigated the polymer droplet formation at the
end of a capillary [151]. When an electric field is applied, the pendant droplet becomes a
cone due to the electrostatic forces being balanced with the surface tension. This cone is now
known as “Taylor cone”. Taylor also found that the diameters of the formed fibres are much
thinner than the diameter of the applied capillary. It is because of the fibre jet is emitted from
the apex of the core. After Taylor, Baumgarten used a high-speed camera to observe a single
fibre formation from the droplet. In 1971, Baumgarten firstly conducted the studies on the
effects of processing parameters and solution properties on the electrospun fibre structures
[152]. Despite these early investigations, electrospinning had not widely been used until the
1990s. In the 1990s, the Reneker group rediscovered and spread the investigation and
application of the electrospinning technology. After that, electrospinning has received
extensive research interest [153, 154].

1.3.1.2 Electrospinning setup and parameters
A typical electrospinning setup consists of three major components: (a) a high voltage power
supply; (b) a spinneret connected with solution supplier; and (c) a conductive grounded
collector. This is schematically shown in Figure 1.17. After feeding a polymer solution to the
spinneret, a droplet of the polymer solution is formed at the tip of the spinneret due to surface
tension. Application of an electric field between the spinneret and collector adds electrical
charges to the droplet. It leads to an electrical force directly opposite to the surface tension.
With increasing voltage of the electric field, the number of surface charges increases until the
electrical force overcomes the surface tension at which point the liquid polymer solution
would be ejected towards the collector. During the movement process of the solution, the
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solvent evaporates and finally polymer fibres would form on the surface of the collector
[155]. Development of more advanced systems that enable production of core-shell fibres, triaxial fibress, multi-tubes fibres, oriented fibres, twisted fibres, and patterned fibres mats can
be achieved by refitting the spinnerets and/or collectors.

Polymer
solution
(b) Spinneret
(a) Power
source
kV
Electrospun Fibres

(c) Collecting substraght

Figure 1.17 Schematics of the experimental setup used to perform electrospinning.

Although electrospinning is simple and easy to manipulate, there are still a range of
processing parameters which can influence the final fibre structure and morphology.
All the parameters can be summarized and divided into three groups: (a) solution properties
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such viscosity, elasticity, conductivity, and surface tension; (b) governing variables such as
hydrostatic pressure in the capillary tube, electric potential between spinneret and collector,
and the distance between the spinneret and collector; (c) ambient parameters such as solution
and air temperature, humidity, and air velocity in the electrospinning environment [155-157].

1.3.1.3 Application of electrospinning to drug delivery systems
Electrospinning has been explored in a wide variety of biomedical application such as tissue
engineering, drug delivery, and biosensors. Applications in drug delivery for fabrication of
carriers, electrospinning affords flexibility in materials selections; both biodegradable and
non-degradable polymers can be electrospun into fibres. Table 1.3 lists the examples of
synthetic and biopolymers that have been electrospun to produce nano- or micro-scale fibres
for use in drug delivery. These matrices have been utilized for delivery of a number of drugs
including antibiotics, anti-inflammatory drugs, anticancer drugs, proteins, DNA, and RNA
[158].

For drug delivery applications, electrospun fibres received much attention because of their
peculiar structures. The thinner fibres possess large surface area to volume ratios. The
porosity of the fibrous mats dramatically further increases the surface areas. Compared with
other polymeric structures, it not only overcomes the limitation of high drug uptake, but also
surmounts the constraint of drug diffusion [159]. This significantly increases the drug release
efficiency. Besides these, it is easy to control the properties of the electrospun mats such as
porosity, diameters, and morphology which can regulate the release kinetics.
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Table 1.3 Examples of electrospun synthetic and biopolymers that have been used for drug
delivery applications [158-160].
Polymer

Structure

Polymer

Solvent

Concentration

Surgical cotton

8 wt%

1-3 wt%

(1140

LiCl/DMAc

Information

Cellulose

polymerization)
Cellulose

N/A

Molecular

Acetate

weight 30 k

Chitin

Molecular

Acetone/Water

10 wt%

HFIP

3-6 wt%

TFA

7 wt%

water

0.25-2 wt%

HFP

10 wt%

weight 920 k

Molecular

Chitosan

weight 210 k
Molecular

Alginate

weight 196 k

Collagen

N/A

From Kensey
Nash

Gelatin

N/A

From Aldrich

TFE

7.5 wt%

Silk

N/A

Bombyx mori

LiBr/water

0.45 g/ml

36

silk cocoons
PLGA

60 k

DMF/

1g/8ml

Dichloroform

PLA

109 k

Dichloroform

5 wt%

PVA

65 k

water

8-16 wt%

PS

190 k

THF

18-35 wt%

PC

80 k

DMF/chlorofor

17 wt%

m

PU

400D

DMF

21 wt%

PEO

400 k

water

7-10 wt%
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PVDF

107 k

DMF

20 wt%

PCL

50 k

Chloroform/met

12 wt%

hanol

Nylon 6

10 k

Formic acid

10 wt%

Electrospinning can be used to load drugs by various methods including coating, embedding,
and encapsulating drugs which lead to well-controlled drug release kinetics. In cases where
both the polymer matrix and drug are soluble in the same solvent, the drug can be
incorporated into the polymer by directly dissolving in the polymer solution [160]. When
they cannot be dissolved in the same solvent, the drug can be dissolved in a solvent that is
miscible with the polymer solution [161]. By these ways, after the electrospinning, the drug
would be embedded in the polymeric fibres. The drug can also be encapsulated in the
polymer using coaxial and emulsion electrospinning [162]. Other popular methods of drug
loading adopted are: where the electrospun fibrous mats are immersed in a drug solution, or
surface coating [163]. Therefore, in these two cases, the drug release mechanisms are
diffusion from the polymer matrix or desorption from the fibre surface.
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1.3.2 Electrospraying
Electrospraying is also another electro-hydrodynamic fabrication method widely applied in
drug delivery [164-167]. Actually, electrospraying is considered as “sister” technology to
electrospinning (Figure 1.18). The only difference is that electrospinning is used for nanomicrofibre fabrication; while electrospraying is used to produce nano- or micro-particles.

As introduced in the electrospinning part, the polymer solution at the tip of the spinneret
would form a Taylor cone. When the electrostatic repulsion surpasses the surface tension,
liquid ejection will occur at the surface of the Taylor cone. If the Taylor cone is stable, the
liquid jet will undergo a whipping or bending motion process, which leads to the formation of
fibres. However, if the Taylor cone is unstable, the liquid jet will break up into droplets and
finally form particles [168]. The different properties of the Taylor cone lead to the difference
between electrospinning and electrospraying. It also depends on the chain entanglement
density of the polymer solution [169]. From the perspective of electrospraying, limiting chain
entanglements will help generate smaller droplets and more uniform microbeads. Chain
entanglements within the drop eventually limit the subdivision of these drops [170, 171].
During the movement of these drops, the solvent evaporates rapidly. Finally, the polymeric
particles with nano-size or micro-size will form on the surface of the collector.
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Figure 1.18 Schematic of the experimental setup used to perform electrospraying.

1.4 Highlights for epilepsy treatment
According to the World Health Organisation, epilepsy is the world’s most common serious
brain disorder; it is more than three times as common as multiple sclerosis, Parkinson’s
disease, and cerebral palsy. It is estimated that around 50 million people in the world have
epilepsy at any one time [172]. Data from Epilepsy Action Australia shows that 800,000
people in Australia will be diagnosed with epilepsy at some stage in their lifetime and up to
5% of the world’s population may have a seizure at some time in their lives. Also, it is
estimated that over 225,000 Australians are living with epilepsy. Approx. 3% to 3.5% of
Australians will experience epilepsy at some point in their lives [173]. Moreover, the impact
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of epilepsy is not only on the person with epilepsy but also the family, and indirectly the
community is affected. This data and situation highlight the significance to develop effective
polymeric nano- or micro-structural drug delivery for local treatment of epilepsy.

Therapeutic interventions for epilepsy currently control seizures in only around 70% of
affected individuals with the remaining people being unresponsive to the current therapeutic
interventions [174-177]. The reasons for this are not currently well understood, but there is a
lot of evidence to suggest that a major reason is the presence of blood-brain barrier [175].
Side effects associated with systemic administration of anti-convulsant drugs include nausea,
rashes, weight changes and dizziness. These side effects are major factors limiting the drugs’
effectiveness in controlling epileptic seizures by preventing the use of higher doses [178180]. Development of effective polymeric nano- or micro-structural drug delivery systems
holds great potential for local treatment of epilepsy. They could be used in the treatment of
multiple independent foci, as well as treatment of seizure foci in eloquent areas of the brain
(Figure 1.19). Local direct delivery may also avoid potential problems of whole-brain and
systemic toxicity encountered in current drug delivery systems.
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b

c

d

Figure 1.19 Schematic illustration of local treatment for epilepsy: a) the onset of preseizures; b) progression into an epileptic seizure event; c) implant local drug delivery system
foci in effective seizure-controlling areas of the brain; d) return to normal situation.
Reproduced from reference [174].

1.5 Aims and structure of this thesis
This thesis aims to develop novel structured implantable or injectable drug delivery systems
for local treatment of central nervous system disorders such as epilepsy.

A variety of

biodegradable polymer microcapsules and 3D conducting polymer drug delivery systems
have been fabricated by electrojetting and electropolymerization techniques, respectively.
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These delivery systems have been systematically characterised, and shown their ability to
control the release profiles of anti-epileptic drugs.

The investigated biodegradable drug delivery microcapsules will possess controllable and
uniform morphology with narrow size distribution, high efficiency drug encapsulation,
sustained and predictable drug release characteristics, and neuro-cytocompatibility. Studies
will also investigate conducting polymer drug delivery systems that will enable electrically
controlled properties, sustained near-linear release, flexible dosage control, and super
stability. Moreover, combined with biodegradable microspheres which contain different
drugs, two interdigitated electrodes may serve as a multi-functional drug delivery system.

The structure of this thesis is summarised in the following sections:
Chapter 1 presents the general introduction and related literature review of this research
field.
Chapter

2 describes the general experimental method relevant to fabrication,

characterization, and drug delivery evaluation.

Chapter 3 describes the preparation and characterization of electrojetted PLGA
microcapsules containing the anti-epilepsy drug, including flattened microspheres,
microspheres, and microfibres. Different microcapsules lead to the variably controllable drug
release profiles, and human neural stem cell culture demonstrates the neuro-cytocompatibility
of the microcapsules.
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Chapter 4 describes the development of a series of core-shell structural microcapsules using
novel core-shell electrojetting. A more hydrophobic polymer shell acts as a barrier
component to control the rate of drug release from the polymeric core, which leads to
prolonged drug release profiles.

Chapter 5 investigates the dual drug delivery systems which are composed of electrospun
microfibres with electrospray microspheres as a composite membrane. These composite
membranes contain two kinds of drugs, and display stable thermal and mechanical properties,
and have promising potential for combined therapy.

Chapter 6 describes an electrically on-demand drug delivery system that consists of threedimensional

printed

interdigitated

electrodes

drug

delivery

systems

coated

by

electropolymerization of a conducting polymer film and electrospray of biodegradable
polymer microspheres. The interdigitated structure provided flexible drug delivery
combinations both for mono drug delivery and dual drug delivery systems.

Chapter 7 provides a summary of the thesis and highlight directions for future research.
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2. CHAPTER 2: GENERAL
EXPERIMENTAL
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2.1 Introduction
In this chapter, the general materials, experimental techniques, and instruments used in this
thesis are briefly described. These include the reagents list, synthesis methods,
physiochemical characterization, and in vitro drug release studies. More details regarding
specific procedures will be presented in the experimental section of each chapter.

2.2 Reagents and materials
The materials used in this thesis are summarized in Table 2.1.

Table 2.1 Information on Reagents and Materials.
Name

Detailed Information

Company

Poly(D,L lactic-co-glycolic

Mw ~ 60,000 Da, molar ratio

Purac, Singapore

acid) (85/15)

of lactide to glycolide 85/15

Poly(D,L lactic-co-glycolic

Mw ~ 60,000 Da, molar ratio

acid) (75/25)

of lactide to glycolide 75/25

Polylactic acid

Mw ~ 180,000 Da

1. Drug Carriers
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Purac, Singapore

Purac, Singapore

Pyrrole monomer

Fresh distilled before use

Sigma-Aldrich

2. Model Drugs

Lacosamide

UCB Pharma Pty Ltd

Phenytoin

Sigma-Aldrich

Dexamethasone

Sigma-Aldrich

fosPhenytoin

Sigma-Aldrich
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3. Release Media related

Phosphate buffered saline

Preparation to 0.001M/L

Sigma-Aldrich

Milli-Q water

Resistivity is 18.2 MΩ·cm at

IPRI

25 oC

Sodium chloride

Analytical Reagent

Sigma-Aldrich

Potassium chloride

Analytical Reagent

Alfa Aesar

Magnesium chloride

Analytical Reagent

Alfa Aesar

Calcium chloride

Analytical Reagent

Sigma-Aldrich

Chloroform

Chemical Pure

Tokyo Chemical Industry

Dimethylformamide

Chemical Pure

Sigma-Aldrich

Methanol

HPLC Grade

Honeywell

Acetonitrile

HPLC Grade

Honeywell

4. Solvents and others
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Trifluoroacetic acid

Analytical Reagent

Chemical Supply

Orthophosphoric acid

Analytical Reagent

Sigma-Aldrich

Paraformaldehyde

For biological purpose

Sigma-Aldrich

Ethanol

For biological purpose

Chemical Supply

2.3 Fabrication methods

2.3.1 Electrojetting
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Syringe Pump

Spinnerets
Collector
Distance

Collector
Control pannel
including High
Voltage Supply
Figure 2.1 Photograph of NANON-01A electrojetting system.

Electrojetting including electrospinning and electrospraying is a simple and versatile
technique to fabricate nano-/micro- fibre and particle [1-4]. All electrojetting experiments
were conducted using a NANON-01A electrojetting system which was purchased from
MECC Co. Ltd, Japan (Figure 2.1). The system is composed of several main parts including
high voltage power supply, syringe and pump, spinnerets, collector, and Controller panel.
Both the spinnerets and collectors can be replaced, depending on the application requirement.
Two kinds of spinnerets are used in this thesis: single tube spinnerets and co-axial spinnerets.
Two kinds of the collector are used: rotating drum and metal plate. The programming
controller panel is used to set parameters such as voltage, feeding volume, and rate of the
solution, the rotation speed of collector, spinnerets movement, etc. The chamber of the
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NANON-01A system can maintain the electrojetting in a stable atmospheric environment
with constant temperature and moisture.

2.3.2 Electropolymerization
Electropolymerization involves the oxidation of the heteroarene to afford radical cations that
couple to form oligomers. The oligomers precipitate to nucleate polymerization on the
electrode surface [5, 6]. In this study, electropolymerization was conducted by using a CHI
600 electrochemical system from CH Instruments, Inc. (Figure 2.2). The instrument contains
a potentiostat with a potential control range of ±10 V; the current range is ±250 mA. It is also
available with a wide variety of electrochemical techniques and is capable of integrated
simulation and fitting software functions for detecting Electrochemical impedance
spectroscopy (EIS) and Cyclic voltammetry (CV). A standard three-electrode cell with a
stainless steel mesh counter electrode (CE) and Ag/AgCl reference electrode (RE) were used
for conducting polymer electrochemical synthesis. The printed 3D Ti-6Al-4V electrode was
used as the working electrode (WE). The electrodes used in this study were 1 cm by 1cm by 1
cm and contain 54 posts. Each post has a ~500 µm diameter and 8 mm height.
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A

B

CH Instruments
Electrochemical workstation

CE

RE

WE

Figure 2.2 Photograph of (A) CHI electrochemical workstation and, (B) schematic of the
three-electrode system.

2.4 General physicochemical characterization
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2.4.1 Scanning electron microscopy
Scanning Electron Microscopy (SEM) is used to observe the microstructure of the materials.
In this thesis, all SEM images were obtained using a JSM7500FA Field Emission Scanning
Electron Microscope from JEOL Ltd., Japan (Figure 2.3). The sample is dried using a
vacuum oven at room temperature to remove any residual organic solvent or moisture.
Typically, the sample is attached to the testing plate with conductive tape. Before SEM
testing, the nonconductive sample is coated with a thin layer of gold to avoid charge
accumulation.

Figure 2.3 JSM7500FA Field Emission Scanning Electron Microscope from JEOL.
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2.4.2 Thermogravimetric analysis
Thermogravimetric Analysis (TGA) is used to investigate the pyrolysis and combustion
behaviour of the materials [7]. TGA is performed on a TGA Instrument Q500 from TA
Instruments, UK (Figure 2.4). It can provide information regarding reactions occurring
during the materials pyrolysis process; such as number and sequence and activation energy
etc. Typically, the sample weight is ~10 mg, the heating rate is set at 10 oC/min, and the TGA
curves are recorded from 50 to 800 oC. In order to eliminate the moisture interference, the
sample is dried in a vacuum oven overnight before TGA testing.

Figure 2.4 Thermogravimetric Analysis Instrument TA Q500.
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2.4.3 Tensile testing
Tensile testing is commonly used to obtain mechanical properties of materials [8]. The
sample used for tensile testing is typically made into a dog-bone shape, subjected to
controlled tension until mechanical failure. The result of tensile testing is given as a stressstrain curve. From this curve, mechanical information such as tensile strength, tensile
modulus, yield strength (not for all kinds of materials), elongation at break can be
determined. The tensile testing is performed by using a commercial Shimadzu EZ-L
mechanical testing machine (Figure 2.5). The sample is gripped by the machine at the two
ends. It is important to make sure that the sample is held tightly without slippage or failure in
the gripped parts.
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Grip
section
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Figure 2.5 Shimadzu EZ-L mechanical testing machine (A) and dog-bone sample (B).
2.4.4 Electrochemical impedance spectroscopy
Electrochemical impedance spectroscopy (EIS) is a powerful diagnostic tool which can be
used to characterize the interface between the electronic and ionic conductor in
electrochemical systems [9]. When conducting impedance testing, a frequency response
analyser is used to impose a small amplitude AC signal to the electrochemical systems and
then measuring the current through the systems.
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WE-3D

CE-Pt
RE-Ag/AgCl
Figure 2.6 The three-electrode system with a Luggin capillary for electrochemical testing.

EIS is measured using a Gamry EIS 3000 TM system with Gamry framework software
employing a three-electrode system (Figure 2.6). The system is made of glass, with a Luggin
capillary in order to minimize the impact of uncompensated electrolyte resistance [10]. The
frequency range was from 0.1 Hz to 100 kHz, and the AC perturbation was 5 mV at open
circuit potential. Data presentation is shown as a Bode Plot in this study. The impedance is
plotted with log frequency on the X-axis and the absolute values of the impedance on the Yaxis.
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2.4.5 Cyclic voltammetry
Cyclic voltammetry (CV) is widely used to study the mechanism, kinetics, electrochemical
active surface area, and thermodynamics of electrochemical reactions [11]. In cyclic
voltammetry, the electrode potential ramps linearly versus time as shown in Figure 2.7.
These ramps can be repeated many times according to experimental requirement. The rate of
voltage change is the scan rate in mV/s. The potential is applied between the working
electrode and the reference electrode, and the current is measured between the working
electrode and the counter electrode. The data is expressed as current vs. applied potential. In
CV, the current flow is a result of the oxidation/reduction process. It is important and useful
in the characterization of materials’ electroactivity. In this study, the CV experiment was
performed using a CHI 600 electrochemical system from CH Instruments, USA. It is tested in
a three-electrode system, using Ag/AgCl reference electrode and Pt mesh as the counter
electrode in aCSF (artificial Cerebral Spinal Fluid) solution.
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Figure 2.7 The classical triangle waveform used in cyclic voltammetry.

2.5 In vitro drug release study

2.5.1 Passive release study of electrojetted microcapsules
Drug release study of electrojetted microcapsules including microparticles, microfibres, and
their hybrid structures is conducted by using a SW23 shaking water bath from John Morris
Scientific Pty Ltd. The water bath is designed to control the temperature and deliver a smooth
reciprocal shaking motion (60 rPm). All samples are immersed in aCSF in a glass vial and
incubated in the shaking water bath. The temperature is set at 37 oC. At appropriate time
intervals, the release medium was withdrawn and replaced with an equal volume of fresh
aCSF.
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2.5.2 Electrically controlled release study of 3D printed electrodes with drug-laden
coatings
The electrically controlled release is carried out in a three-electrode system by a using CHI
600 electrochemical system from CH Instruments, USA. An Ag/AgCl electrode is used as a
reference electrode; the stainless steel mesh is used as counter electrode. For two
interdigitated electrodes release study, one electrode is used as the counter electrode. A
square wave, biphasic voltage stimulation is used for electrical stimulation to trigger drug
release. The detailed information relating to voltage stimulation is shown in Figure 2.8. After
several stimulations, the released solution is sampled each time.
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Figure 2.8 Applied potentials of the square wave, biphasic voltage stimulations
used in the electrically controlled release study.
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2.5.3 High Performance Liquid Chromatography Analysis

Figure 2.9 Photograph of Agilent 1260 Infinity High Performance Liquid Chromatography
system.

High Performance Liquid Chromatography (HPLC) has wide application in analytical
chemistry for separation, identification, quantification of chemical components in a mixture
[12]. HPLC analysis of aCSF containing released drugs was conducted on an Agilent 1260
Infinity HPLC system (Figure 2.9). The analytical column used here is an Atlantis® T3 C18
column (5 µm, 250 mm × 4.60 mm). The mobile phase, mobile phase flow rate and the UVvis detection wavelength are detailed in each chapter. The amounts of released drugs are
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calculated according to pre-established calibration curves (Figure 2.10). All the error bars
data shown in figure are expressed as mean+/- standard division.

Lacosamide

Dexamethasone

Fos-phenytoin

Phenytoin

Figure 2.10 The pre-established calibration curves of model drugs used in this thesis
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3. CHAPTER 3: DEVELOPMENT OF
DRUG-LOADED POLYMER
MICROCAPSULES FOR
TREATMENT OF EPILEPSY
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3.1 Introduction
Approximately 90% of the new drugs that are successful in preclinical studies fail in clinical
trials[1]. The high failure rate in new drug development is not due to a lack of drug potency,
but rather due to toxicity, side effects, and poor pharmacokinetics and pharmacodynamics. A
promising strategy for overcoming these drawbacks is to develop an appropriate drug
delivery system for targeted and efficient application. For treatment of brain diseases, such as
epilepsy, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and brain tumours,
drug delivery to the central nervous system (CNS) represents a unique challenge. This is due
to a number of factors, in particular the presence of physical permeability barriers such as the
blood-brain barrier (BBB) and the blood-cerebrospinal fluid (blood-CSF) barrier, and
expression of multidrug drug efflux transporters at the barriers, which work collectively to
restrict the entry of many pharmaceuticals into to the brain [2-6]. The low brain permeability
of many drugs is responsible for drug resistance in the therapies for many diseases. In the
case of epilepsy, 30-40% of patients remain drug resistant with poor clinical outcomes, and
this represents a significant hurdle for medication therapy of intractable epilepsy [7].

In order to deliver drugs to the brain, considerable effort has been made to develop
nanocarriers for systemic delivery of therapeutics [8-14]. Compared to systemic drug
delivery, local drug delivery to the site of action offers the potential to improve the
therapeutic efficacy of epilepsy medication. It directly bypasses the physical brain barriers,
which may result in improved drug delivery efficiency and bio-distribution. Consequently, a
lower therapeutic dosage may be required, with a concomitant reduction in side effects [1517]. These advantages have motivated the research and development of local drug delivery
systems for treatment of epilepsy [18-21]. For example, Williamson et al. developed an
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organic electronic ion pump, composed of poly(3,4-ethylenedioxythiophene) doped with
polystyrene sulfonate electrodes, for on-demand and site-specific delivery of an inhibitory
neurotransmitter, gamma-aminobutyric acid (GABA). The delivery of GABA was shown to
result in quick and localized suppression of epileptiform activity [21]. Pritchard et al.
developed silk fibroin coatings on solid reservoirs of the anticonvulsant adenosine. By
modulating the coating thickness and crystallinity, sustained release of adenosine with
various release profiles including zero-order release profiles was achieved over a period of
two weeks [19].

Lacosamide, the R-enantiomer of 2-acetamido-N-benzyl-3-methoxypropionamide, is a novel
antiepilepsy drug. Based on the efficacy and therapeutic index observed in a range of animal
models of epilepsy at the National Institute of Health (NIH) Anticonvulsant Screening
Program, lacosamide warranted further evaluation and was subsequently developed as an
AED for both oral and intravenous use. It is suggested that lacosamide has a dual action
underlying its anticonvulsant and analgesic properties. It has also been found that lacosamide
selectively enhances slow inactivation of voltage-gated sodium channels without affecting
fast inactivation [7].

This chapter aims to fabricate microcapsules using a simple electrojetting (electrospinning
and electrospraying) technology, for the sustained delivery of antiepilepsy drugs (AEDs). The
microcapsules include flattened microspheres, microspheres, and microfibres, which have
controllable uniform morphology and size distribution, enable high-efficiency drug
encapsulation, and have release profiles that agree well with the mathematical simulation
model results, and thus are predictable. Importantly, the microcapsules are compatible with
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human NSCs (Neural Stem Cells) and derivative neurons and neuroglia, which is indicative
of clinical compliance for therapeutic use. These microcapsules can be utilized as
injectable/implantable systems for site-specific delivery of AEDs.

3.2 Materials and Methods

3.2.1 Materials
The anti-epilepsy drug, lacosamide, was provided by UCB Pharma Pty Ltd. Poly(D,L- lacticco-glycolic acid) (Mw ~ 60,000 Da, with a 75/25 molar ratio of lactide to glycolide) (PLGA
75/25) was purchased from Purac, Singapore. Chloroform, methanol, and acetonitrile were all
analytical grade from Sigma-Aldrich. All the others chemicals and reagents were purchased
from Sigma-Aldrich and used as received.

3.2.2 Microcapsule fabrication via electrojetting
The microcapsules, including microspheres and microfibres, were fabricated using NANON01A electrospinning system (MECC Co. Ltd, Japan) at ambient temperature. A range of
PLGA/lacosamide (w/w, 10/1) solutions were prepared in chloroform, with the PLGA
concentration varying from 1.5 wt%, 4.5 wt%, to 14.0 wt%, respectively. After encapsulation
efficiency testing, drug loadings of 8.91 %, 9.20 %, and 9.23 % were achieved. For
electrojetting, each solution was loaded into a plastic syringe equipped with a 23-gauge
87

stainless steel needle. The distance between the tip of the needle and the aluminium foil was
12 cm, and the voltage was 10 kV for electrospraying and 21 kV for electrospinning. The
feed rate was controlled at 0.5 mL/h using a syringe pump, and the electrojetted samples were
collected using aluminium foil.

3.2.3 Morphological and dimensional statistical analysis
A field emission scanning electron microscope (FESEM, JEOL JSM-7500FA) was used to
examine the morphologies of the as-fabricated microcapsules. The samples were sputtercoated with 20 nm gold prior to SEM testing. The dimensional statistical analysis was
conducted by quantitatively evaluating the high-magnification SEM micrographs using the
imaging software, Leica Application Suite.

3.2.4 In vitro drug release study
The drug release was conducted in artificial cerebrospinal fluid (aCSF) at 37 oC in a shaking
water bath. Each sample was immersed in 1 mL of aCSF, and the released solution was
removed at various time points and replaced with 1 mL of fresh aCSF. All samples were kept
at -20 oC, before being analysed by high performance liquid chromatography (HPLC). HPLC
analysis was conducted using an Agilent 1260 Infinity HPLC system. The analytical column
used was an Atlantis® T3 C18 column (5 µm, 250 mm × 4.60 mm). The mobile phase
consisted of Milli-Q water, acetonitrile (HPLC grade) and methanol (HPLC grade)
(65:26.2:8.8, v/v/v). The mobile phase flow rate was 0.8 mL/min, and the UV-vis detection
wavelength was 210 nm [20]. The amounts of released drug were calculated according to a
pre-established calibration curve. An extraction method was used to determine the drug
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encapsulation efficiencies of the as-fabricated core-shell microcapsules. Briefly, each sample
(1 cm × 1 cm) was placed into 1 mL methanol for 12 hours, after which the methanol was
removed and replenished with 1 mL of fresh methanol. This extraction procedure was
repeated four times, with each methanol sample being allowed to evaporate to leave the
residual drug behind, which was reconstituted using artificial cerebrospinal fluid (aCSF,
0.866 wt% NaCl, 0.224 wt% KCl, 0.0164 wt% MgCl2·6H2O, and 0.0206 wt% CaCl2·6H2O in
0.001M Phosphate Buffer Solution). Each aCSF sample was then analysed for drug content
using HPLC. The 4th reconstituted sample revealed an absence of the drug, indicating that
the entire drug had been extracted from the electrojetted sample [22].

3.2.5 Mathematical modelling of the release profiles of the microcapsules
The release profiles of the microcapsules were simulated using Fick’s second law of diffusion
subject to appropriate boundary conditions [23, 24]. When the surface resistance to mass
transfer at the surface is negligible, the fraction of the drug released from the microcapsules
(Mt/M∞) at any time (t) can be expressed as follows:

∞
M𝑡
𝑀∞

=1−∑
𝑛=0

2𝑖
𝜆𝑛 2

𝑒

−

4𝜆𝑛 2 𝐷𝑒 𝑡
𝑑2

(3.1)

Where, 𝑑 is the diameter of the microcapsules, 𝐷𝑒 is the effective diffusivity of drug, 𝑖 = (2,
3, 3) and 𝜆𝑛 = (nπ) for flattened microspheres and microspheres, 𝜆𝑛 = (2.41, 5.52, 8.65, 11.8,
14.93···) for microfibre[25] (International system od units). The mathematical modelling
study are based on equation (1), using MATLAB Curve Fitting Toolbox.
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3.2.6 NSC culture and differentiation
Working stocks of human NSCs (ReNcell CX, SCC007, Millipore) were maintained under
5% CO2 at 37 oC, seeding at a density of 2 – 3 x 106 cells in proliferation medium comprising
NeuroCult NS-A (#5751, Stem Cell Technologies) with 2 µg/mL heparin, 20 ng/mL FGF2
and 20 ng/mL EGF (AF-100-15, Peprotech) on laminin (L6274, Life Technologies) coated 6well plates (Greiner Bio-One). Cells were passaged at confluency every 5-7 days by digesting
in TrypLE (Life Technologies) for 3 min at 37 oC. Differentiation of NSCs was performed 3
days after initially seeding in proliferation medium, using neural differentiation medium
comprising two parts DMEM/F-12 (11330-032, Life Technologies), one part Neurobasal
(21103-049, Life Technologies) supplemented with 0.5% N2 (17502048, Gibco) and 50
ng/mL brain-derived neurotrophic factor (BDNF, 450-02, Peprotech) for up to 10 days.

3.2.7 NSC viability analysis
PrestoBlue™ cell viability reagent was used for NSC viability studies, according to the
manufacturer’s instructions. Briefly, cells were incubated with the reagent in culture medium
for 1 hr at 37 oC. Following incubation, for each sample, 100 µL supernatant was transferred
to a well of a 96-well plate and screened by a microplate reader (POLARstar Omega) to read
fluorescence intensity. After processing, samples were rinsed in culture medium and returned
to culture, with the process repeated for each time point until the study was completed.
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3.2.8 Scanning Electron Microscopy (SEM)
SEM was performed as previously described [26]. Briefly, samples were fixed in 3.7%
paraformaldehyde (PFA) for 10 min and then serially dehydrated in 30%, 50%, 70%, 85%,
95%, and 100% ethanol before Critical Point Drying using a LeicaEMCPD030 instrument.
The samples were then coated with 20 nm platinum followed by imaging with a JEOL JSM7500FA.

3.3 Results and Discussion

3.3.1 Fabrication of lacosamide-loaded microcapsules by electrojetting
Electrojetting is an electrohydrodynamic process. It is a simple, versatile and cost effective
technology that employs an electrically charged jet of a polymer solution to fabricate nano- or
micro- scale fibres (i.e., electrospinning) or particles (i.e., electrospraying) [27-31].
Electrojetting is governed by the interactions between the electrostatic repulsion induced by
an applied electric field and surface tension of a liquid droplet. At the tip of the capillary, due
to the electrostatic repulsion and the surface tension, the hemispherical surface of the polymer
droplet is distorted into a conical shape that is known as the Taylor cone. When the
electrostatic repulsion surpasses the surface tension, liquid ejection will occur at the surface
of the Taylor cone. Electrospinning (as is illustrated in Figure 3.1) typically occurs when the
polymer concentration and molecular weight are sufficiently high so that the Taylor cone is
stable, and the fluid does not break up into droplets but forms a stable liquid jet. The liquid jet
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will undergo a whipping or bending motion process, giving rise to the formation of fibres
[27].

kV

Power source

Syringe and Pump

Collector

PLGA Solution

Fiber Formation

+++
++
+
++++
Stable Taylor Cone

Microfiber
Figure 3.1 Schematic illustration of the electrospinning setup, with SEM images of
electrospun PLGA/lacosamide microfibres. The scale bar is 10 µm.

However, when the polymer concentration is below a threshold and/or the polymer molecular
weight is low enough, the Taylor cone becomes unstable, and the liquid jet breaks up due to
varicose instabilities and hence fine droplets are formed. The electrostatic forces among the
droplets enable self-dispersing of the droplets in space with minimal droplet agglomeration.
Further evaporation of the solvent leads to concentration and solidification of the droplets,
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i.e., the formation of the polymeric microspheres. This process is also

known as

electrospraying, which is illustrated in Figure 3.2 [32].

kV

Power source

Syringe and Pump

Collector

PLGA Solution

Sphere Formation

+++
++
+ Unstable
++++Taylor Cone

Microsphere
Figure 3.2 Schematic illustration of the electrospraying setup, with SEM images of
electrospray PLGA/lacosamide microspheres. The scale bar is 10 µm.

Therefore, under a given electric field, the difference between electrospinning and
electrospraying lies in the chain entanglement density of the polymer solution [30]. In this
study, the only variable affecting the chain entanglement density is the PLGA concentration.
The final electrojetted structure is mainly determined by the PLGA concentration. By
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carefully varying the PLGA concentration in the solutions, three kinds of microcapsules have
been fabricated, including flattened microspheres, microspheres, and microfibres.

c

a

2 µm

2 µm

b

d

20 µm

20 µm

Figure 3.3 Scanning Electron Microscope (SEM) images of PLGA/lacosamide a, b)
Flattened microspheres, c, d) Microspheres.

Here shown are the SEM micrographs of lacosamide-loaded flattened microspheres (obtained
from 1.5 wt% PLGA and at 10 kV), microspheres (obtained from 4.5 wt% PLGA and at 10
kV), and microfibres (obtained from 14 wt% PLGA and at 21 kV). Our study shows that
electrospraying led to the formation of either flattened microspheres or microspheres (Figure
3.3), while electrospinning led to the formation of microfibres (Figure 3.4).
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a

2 µm

b

20 µm

Figure 3.4 Scanning Electron Microscope images of PLGA/lacosamide Microfibres.
These results are consistent with the previous studies, where the polymer concentration is
demonstrated to be the most critical parameter in determining the morphology of electrojetted
microcapsules [24, 30]. In the current study, at a low PLGA concentration such as 1.5 wt%
and 4.5 wt%, even with an increased applied voltage of up to 21 kV, only micro-spherical
structures were fabricated.
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3.3.2 Dimensional and shape uniformity analysis
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Solution concentration (wt %)
Figure 3.5 Size of flattened microspheres, microspheres, and microfibres.

Evaluation of the dimensional and shape uniformity was conducted by analysis of the SEM
images of the as-prepared microcapsules. As shown in Figure 3.5, the diameters are
3.01±0.51 µm for the flattened microspheres, 5.10±0.78 µm for the microspheres, and
1.38±0.15 µm for the microfibres, respectively. The diameter distribution of each kind of the
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microcapsules is shown in Figure 3.6, respectively. All the as-fabricated microcapsules
demonstrate uniform morphology with narrow size distribution.
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Figure 3.6 Size distributions of flattened microspheres, microspheres, and microfibres.
.
For electrospinning, as the PLGA concentration is high at 14 wt%, sufficient polymer
entanglements are present and responsible for the formation of a stable liquid jet of PLGA
that undergo continuous stretching during the whipping or bending motion process.
Compared to the microcapsules produced by electrospray, the diameters of the electrospun
microfibres are much thinner [33].
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b
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1 µm

20 µm
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Figure 3.7 Aspect ratio of PLGA/lacosamide a, b) flattened microspheres and c, d)
microspheres; Aspect ratio defined as the ratio of the l to w as shown in figures.

For electrospraying, the dimension and shape of the microcapsules are controlled by these
two processes: rapid solvent evaporation of the droplets, and polymer diffusion during
evaporation. However, rapid solvent evaporation and polymer diffusion do not necessarily
lead to spherical microspheres. When a lower PLGA concentration, such as 1.5 wt%, was
used in this present work, flattened morphology is formed. This is probably due to incomplete
solvent evaporation, as such the electrosprayed microcapsules are still in liquid form when
reaching the collector [34]. Increasing the polymer concentration to 4.5 wt% prompts the
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formation of spherical microspheres with increased particle sizes; since increasing the
polymer concentration leads to an increase in the solution viscosity and a reduction in the
surface tension. In accordance with Hartman’s study, decreasing the surface tension results in
increasing the size of electrospray PLGA microspheres [35].
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Microspheres
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0.88

0.80

PLGA concentration (4.5 wt%)

Figure 3.8 Statistical results of aspect ratio, a) flattened microspheres and b) microspheres.
Aspect ratio (AR), expressed as l to w (shown in Figure 3.7), is an important parameter to
evaluate the shape uniformity of the particles. The dimensions of flattened microspheres and
microspheres were measured in two perpendicular directions. The AR of the microspheres is
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1.03 for the microspheres, and 1.05 for the flattened microspheres (Figure 3.8). Both kinds of
microcapsules possess excellent shape uniformity.

3.3.3 In vitro drug release and mathematical modelling study

Drug Loading efficiency (%)
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microspheres, microspheres, and microfibres.

As shown in Figure 3.9, all the microcapsules exhibit ultra-high drug encapsulation
efficiency. They are 89.1±6.9 % for flattened microspheres, 92.0±3.5 % for microspheres,
and 92.3±2.1 % for microfibres. These encapsulation efficiencies are significantly greater
than those prepared using other techniques, including emulsion, suspension, and emulsion
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polymerization [36], solvent evaporation [36, 37], spray drying [38], and layer-by-layer
encapsulation [39].

Cummulative Release (%)

120
100
80
60
40

Flattened microsphere
Microsphere
Microfiber

20
0
0

50

100

150

200

250

Time (h)

Figure 3.10 Cumulative release profiles of various PLGA microcapsules.

Figure 3.10 shows the in vitro drug release profiles of the flattened microspheres,
microspheres, and microfibres. The release profiles vary significantly with the shape and
morphology of the microcapsules. While the microfibres demonstrate the least initial burst
release, the flattened microspheres exhibit the most rapid release characteristics, with more
than 95% of the lacosamide being eluted within ~52 hours. Within the same period, the
cumulative release of the lacosamide from the microspheres and microfibres is approximately
74% and 55% of the respective total drug loading.
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From the perspective of clinical application, for short term seizure prophylaxis, such as after
brain surgery, quick early release to a therapeutic level would be preferred. However, the
microfibres are more clinically useful as they afford a longer duration of release. An ideal
implantable seizure control device should further improve the kinetics to provide as even and
as long-term release as possible over the duration of the implant [18]. The fabrication
methods demonstrated here have the potential for further improvement after easy
modification. For example, application of core-shell spinnerets to fabricate core-shell
microfibres can significantly prolong release time [16]. Besides these, use of a more
hydrophobic polymer as drug carrier is another promising option.

Typically, drug release from biodegradable microcapsules is controlled by diffusion at an
initial stage and then a combination of diffusion and erosion at the later stage [40]. During
incubation in the release medium, drug diffusion occurs initially within a thin surface layer,
and subsequently with water penetration into the bulk of the microcapsules, enhanced
diffusive transport of the remaining lacosamide in the microcapsules occurs. Therefore, the
morphology and dimension of the PLGA microcapsules have a significant influence on the
release of lacosamide. Most of the reported mathematical modelling studies for biodegradable
microcapsules drug delivery systems are based on a single, zero-order process; or a process
that is governed only by diffusional mass transfer or chemical reactions [41]. In order to more
accurately predict drug release kinetics for biodegradable microcapsules, mathematical
models that take account of the effects of composition and geometry (size and shape) on the
drug release are required.
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In this study, it is assumed that drug release from those microcapsules is predominantly
diffusion-controlled within the period of study. This assumption is based on our and others’
in vitro studies that showed minimal polymer degradation of the microcapsules within a
period of up to three weeks [20, 24, 41]. According to Fick’s second law of diffusion, the
fraction of the released drug from the microcapsules (Mt/M∞) at any time (t) can be expressed
as equation (1). In this model, a well-mixed external aqueous phase with a negligibly small
drug concentration is assumed. And the drug is assumed to be homogeneously distributed
throughout the polymer matrix with an initial drug concentration higher than the solubility of
the drug in the polymer. For the microfibres geometry, the drug diffusional release is
considered from a cylindrical matrix. The eigenvalues 𝜆𝑛 , the roots of eigenfunctions are
𝜆𝑛 =2.41, 5.52, 8.65, 14.93, and so on [25]. The mathematical model can be expressed as:
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For the flattened microspheres and microspheres geometry, the diffusional drug release is
considered from a spherical matrix. The eigenvalues 𝜆𝑛 , the roots of eigenfunctions are 𝑛𝜋.
The equation (3.1) can be expressed as:
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(3.3)

Figure 3.11 Comparison of the mathematical modelling results (linear) with experimental
drug release profiles (dots).

Figure 3.11 shows the least-squares fitting results by applying these mathematical models.
The initial drug loading is determined by encapsulation efficiency testing results of HPLC.
Our results demonstrated that drug release profiles using the above models could be predicted
with a very good agreement with the experimental drug release data. The computed effective
diffusivities (𝐷𝑒 ) are 3.29×10-12 cm2/min for flattened microspheres, 1.89×10-12 cm2/min for
microspheres, and 1.23×10-13 cm2/min for microfibres, well within the range of values
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previously reported for hydrophobic drugs in PLGA microcapsules [23]. Compared with the
flattened microspheres and microspheres, the microfibres possess the lowest effective
diffusivities (𝐷𝑒 ) during this time-dependent diffusion process.

3.3.4 Human neural stem cell viability and differentiation

a

10 µm

b

10 µm

Figure 3.12 Human NSC viability and on a) microfibres and b) microspheres. NSCs were
cultured with fibres and spheres following successful attachment.
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Demonstration of neuro-cytocompatibility of these electrojetted spheres and fibres was
carried out by using clinically relevant human brain tissue derived NSCs and their
differentiation to neurons and supporting neuroglia.

Figure 3.13 Human NSC viability and proliferation kinetics during culture with microfibres
and microspheres.

Neurocompatibility was supported by cell attachment (Figure 3.12) and viability (Figure
3.13) during extended cell culture with fibres and spheres. NSC viability studies indicated
cell proliferation on all substrates (Figure 3.14), similar to the control (Figure 3.15).
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a

b

10 µm

1 µm

c

d

10 µm

1 µm

Figure 3.14 Morphology of differentiated human NSCs during culture with microfibres and
microspheres.

In all cases, quantitative measurement of cell viability marker PrestoBlue® supported normal
growth kinetics, with cell proliferation increasing exponentially up to 8 days culture. As
expected, cell viability decreased following peak cell growth, reflecting the limits of culture
due to media exhaustion [42].
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a

10 µm

b

1 µm

Figure 3.15 Morphology of differentiated human NSCs during conventional plate-based
culture, used as the control for comparison.
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Figure 3.16 Immunophenotyping of differentiated NSCs. DAPI (blue) colocalised with
neuronal markers MAP2 (green), and TUJ1 (red), and glial marker GFAP (purple) expressed
by differentiated NSCs cultured with microspheres. scale bar: 50 µm.

Importantly, differentiation of NSCs resulted in neuronal cells cultured for up to 10 days with
densely packed neurites adhering to the fibres and spheres. Immunophenotyping confirmed
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successful differentiation and co-culture of spheres and fibres with MAP2 and TUJ1
expressing neurons (Figure 3.16) and GFAP expressing glial cells (Figure 3.17).

MAP2

DAPI

GFAP

50 µm

DAPI

TUJ1

50 µm

Figure 3.17 Immunophenotyping of differentiated NSCs. DAPI (blue) colocalised with
neuronal markers MAP2 (green) and TUJ1 (red), and glial marker GFAP (purple) expressed
by differentiated NSCs cultured with microfibres. Scale bar: 50 µm.
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3.4 Conclusion
In conclusion, microstructured drug delivery systems have been fabricated by using a simple
electrojetting (electrospraying and electrospinning) technology for local delivery of AEDs.
These microcapsules have demonstrated a number of advantages, including controllable and
uniform morphology and narrow size distribution, high efficiency drug encapsulation,
sustained and predictable drug release characteristics, and neuro-cytocompatibility as
evidenced by human NSC support and differentiation. Our findings broadly support the
utility and efficacy of the local drug delivery systems for treating human brain disorders such
as epilepsy. In addition, the method presented here could be applicable to the fabrication of
other microstructured delivery systems using different drugs and/or polymers.
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4. CHAPTER 4: CORE-SHELL
MICROCAPSULATION OF ANTIEPILEPTIC DRUGS
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4.1 Introduction
Epilepsy is a long-term neurological disorder, affecting more than 60 million people
worldwide. It is characterized by recurrent and unpredictable seizures, which can cause loss
of consciousness, falls and injury, psychosocial disability, and even mortality. Medication
provided via oral administration is the first approach to epilepsy treatment, but controls only
up to 70% of the cases, whilst the rest of the patients remain incompletely responsive to
medication [1, 2]. The reasons for this are not yet fully understood, but there is a significant
body of evidence pointing to the blood-brain barrier (BBB) [3]. The BBB protects the brain
from harmful blood-borne substances and microorganisms by separating the brain
parenchyma from the circulating blood. Such self-protection also poses an obstacle to drug
delivery to the brain. Nearly 100% of high molecular weight drugs and >98% of low
molecular weight drugs are excluded from the brain [4-6]. For instance, a typical dosage of
an antiepilepsy drug (AED), such as lacosamide (used in this study), is 400 - 500 mg per day
[7, 8] by oral administration. However, the actual amount of lacosamide arriving at the sites
of seizures is very limited due to the limited ability of the drug to cross the BBB [3].
Moreover, this high systemic dosage causes serious whole body side-effects, such as rashes,
nausea, and weight changes.

For patients whose seizures cannot be controlled by medications, surgery represents an
alternative option, which can be provided only to appropriately selected patients, where the
seizure origin in the brain can be localized. In addition, a comprehensive pre-surgical
assessment must be conducted in order to ensure the benefits of the operation. Following
surgical therapy, the patients still need to take AEDs for a long time to prevent epilepsy
relapse [9, 10].
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To improve epilepsy control, local drug delivery through microinjection or implantation in
the brain to bypass the BBB may offer an innovative approach to improve the efficacy of the
medication. This approach can significantly reduce the dosage of AEDs, while concurrently
minimising the side effects associated with systemic administration of AEDs [11, 12]. In
addition, compared to surgical resection, direct injection or implantation would significantly
reduce potential brain damage [13].

An ideal local drug delivery system should be biocompatible, biodegradable and exhibit an
optimal drug release profile pertaining to the targeted application. It should also be amenable
to fabrication and large scale production. Poly(lactic-co-glycolic acid) (PLGA) has been
intensively studied for local drug delivery [14-16]. In particular, it has been explored in
treating central nervous system disorders, such as Alzheimer’s [17, 18] and Parkinson’s [19,
20] diseases, as well as in treating brain injury [21], demonstrating excellent brain
biocompatibility. Lacosamide was selected as a model drug based on its efficacy and
therapeutic index [22]. In terms of material fabrication, electrojetting, such as electrospinning
and electrospraying, has attracted tremendous interest in recent years [23-28]. It is a low-cost
and versatile technique for uniform fabrication of polymer structures ranging from nanoscale
to microscale [29-31]. However, only limited studies have been undertaken on the
electrojetted systems in terms of morphology, drug encapsulation efficiency and drug release
characteristics [31, 32]. Moreover, to the best of our knowledge, no study has yet to be
reported on core-shell structured electrojetted systems.

This chapter aims to apply a novel electrojetting technique for the fabrication of core-shell
microspheres and microfibers, where AED-laden polymer cores are surrounded by drug-free
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polymer shells that act as a barrier in order to regulate drug release characteristics. A variety
of

core-shell

PLGA/lacosamide

microcapsules,

including

microflakes,

flattened

microspheres, microspheres, microsphere-fibres, beaded microfibres, and microfibres, have
been developed with narrow size distribution and uniform morphology. These systems
demonstrated high efficiency in drug encapsulation and sustained drug release characteristics,
which makes them promising candidates as injectable microspheres and polymer implants for
local drug delivery for epilepsy control.

4.2 Materials and methods

4.2.1 Materials
Poly(D,L-lactic-co-glycolic acid) (PLGA) (Mw ~ 60,000 Da) with various molar ratio of
lactide to glycolide, including PLGA 75/25 (lactide/glycolide = 75/25) and PLGA 85/15
(lactide/glycolide = 85/15), were purchased from Purac, Singapore, and used as received.
Lacosamide, an anti-epilepsy drug, was provided by UCB Pharma Pty Ltd. All the other
chemicals and reagents were purchased from Sigma-Aldrich.

4.2.2 Electrojetting (electrospinning and electrospraying)
A range of solutions of PLGA 75/25 and lacosamide were prepared as the core solutions for
electrojetting. In these solutions, the ratio of polymer/drug (w/w) was kept constant at 10/1,
while the polymer concentration was varied from 0.75 to 15 wt%. After encapsulation
efficiency testing, drug loadings of 9.06 %, 9.11 %, 9.40 %, 9.53 %, 9.49 %, and 9.92 % were
achieved. A range of drug-free PLGA 85/15 solutions were prepared as the shell solutions for
electrojetting, with the polymer concentration ranging from 0.5 to 10 wt%.
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Electrojetting (electrospinning and electrospraying, respectively) was conducted at room
temperature using a NANON-01A electrospinning system (MECC Co. Ltd, Japan). A coaxial
spinneret with 0.2 mm

core and

0.8 mm

sheath

nozzles were connected to the core

and shell solutions. The distance from the spinneret tip to the collector was maintained at 12
cm, and the applied voltage for electrospinning and electrospraying was 21 kV and 10 kV,
respectively. The feed rate was 0.1 mL/h for the core solutions and 0.4 mL/h for the shell
solutions. Aluminium foil was used to collect the fabricated core-shell microcapsules, and the
samples were further dried in a vacuum oven at room temperature for 48 hours to remove any
residual organic solvent.

4.2.3 Morphological and dimensional statistical analysis
The morphologies of the as-prepared microcapsules were examined using a Field Emission
Scanning Electron Microscope (FESEM, JEOL JSM-7500FA). The samples were sputtercoated with 20 nm gold to avoid charge accumulation. The dimensional statistical analysis
was conducted by analysis of the SEM micrographs using the imaging software, Leica
Application Suite. All data were expressed as mean ± standard deviation (SD).

4.2.4 Determination of drug encapsulation efficiency
An extraction method was used to determine the drug encapsulation efficiencies of the asfabricated core-shell microcapsules. Briefly, each sample (1 cm × 1 cm) was placed into 1
mL methanol for 12 hours, after which the methanol was removed and replenished with 1 mL
of fresh methanol. This extraction procedure was repeated four times with each methanol
sample allowed to evaporate to leave residual drug behind. And the methanol extracts were
quantified by HPLC to determine the respective drug encapsulation efficiency.
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The details of the HPLC testing method were refer to previous work [33]. The amounts of
released drug were calculated according to a pre-established calibration curve that was
obtained by plotting the peak areas against respective concentrations of a range of standard
lacosamide solutions prepared in aCSF.

4.2.5 In vitro drug release study
In vitro drug release was conducted in artificial cerebrospinal fluid (aCSF). Each sample (1
cm × 1 cm) was incubated in 1 ml of aCSF at 37 oC in a shaking water bath. At appropriate
time intervals, the release medium was withdrawn and replaced with 1mL of fresh aCSF. The
released samples were stored at -20 oC prior to the HPLC analysis for quantification of the
amounts of the lacosamide released. The results were shown as cumulative release vs time. A
line was used to connect the sample dots of the appropriate time intervals. The results were
quite different from the modelled data presented in Chapter 3.

4.3 Results and Discussion

4.3.1 Preparation of various forms of electrojetted core-shell microcapsules
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Figure 4.1 Schematic illustration of the electrojetting setup, electrospinning of core-shell
microfibres.

Electrojetting, including electrospinning and electrospraying, represents a simple and
versatile method for producing monodisperse polymeric spheres and fibres at the nano- and
micro-scale [23, 34]. Electrojetting is governed by the interactions between the electrostatic
repulsion induced by an applied electric field and surface tension of a liquid droplet. When
the electrostatic repulsion surpasses the surface tension to a critical point, liquid ejection will
occur at the surface of the droplet. The liquid jet will undergo a whipping process, which
leads to the formation of either fibres (electrospinning, as shown in Figure 4.1), or spheres
(electrospraying, as shown in Figure 4.2) at the nano- or micro-scale. Therefore, the final
electrojetted structure is determined by the electric force applied and the properties of
polymer solutions. The polymer solution properties are governed by the molecular weight
and concentration of the polymer, as well as the solvent properties.
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Figure 4.2 Schematic illustration of the electrojetting setup, electrospraying of core-shell
microspheres.

In this study, PLGA 75/25 and lacosamide were used as the core structural materials, whilst
PLGA 85/15, a

more hydrophobic copolymer, was used as the shell material [35].

Chloroform was used as the solvent, with a low boiling point of 61.2 oC. By adjusting the
applied voltage and screening of the concentrations of the core and shell solutions,
microcapsules with various shapes, including microflakes, flattened microspheres,
microspheres, microspheres-fibres, beaded microfibres, and microfibres, were successfully
fabricated.
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Table 4.1 Microcapsules with various structures and their respective fabrication conditions.
Sample
Code

Core PLGA
(75/25)
concentration
(wt %)

Shell PLGA
(85/15)
concentration
(wt %)

Applied Voltage
(kV)

Type of microcapsule
formed

S0w

0.75

0.5

10

Microflakes

S2w

3

2

10

Flattened microspheres

S4w

6

4

10

Microspheres

S5w

7.5

5

10

Microspheres-fibres

S8w

12

8

21

Beaded microfibres

S10w

15

10

21

Microfibres

These microstructures, together with their respective fabrication conditions, including the
concentrations of the core and shell solutions and voltage, are summarised in Table 4.1. For
electrospraying of microflakes, flattened microspheres, microspheres or microspheres-fibres,
a 10 kV voltage was used, whereas for electrospinning of beaded microfibres or microfibres,
a 21 kV voltage was used.

4.3.2 Morphological and dimensional statistical analysis
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f
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Figure 4.3 Scanning Electron Microscope (SEM) images of various core-shell PLGA
microcapsules; a, b) Microflakes, c, d) Flattened microspheres, e, f) Microspheres.

During the electrojetting process for fabrication of the microflakes or flattened microspheres,
both the polymer concentrations in the core and shell solutions are very low (Table 4.1). This
results in the rapid collapse of PLGA microcapsules during solvent evaporation and polymer
solidification, to produce the microflakes (Figure 4.3 a,b) and flattened microspheres
127

(Figure 4.3 c,d) with a rough, pitted and porous surface topography [36]. At higher PLGA
concentrations, such as 6 wt% of the core solution and 4 wt% of the shell solution,
microspheres (Figure 4.3 e,f) are produced, exhibiting a much smoother surface.

a

b

2 µm

20 µm

c

d

20 µm

2 µm

Figure 4.4 Scanning Electron Microscope images of various core-shell PLGA a, b)
Microspheres-fibres, c, d) Beaded microfibres.

Further increasing the PLGA concentrations to 7.5 wt% for the core and 5 wt% for the shell
results in the concurrent formation of microspheres and microfibres (Figure 4.4), where the
diameters of fibres are much thinner than those of the microspheres. The portion of the
microfibres in the microcapsules increases with increasing polymer concentrations.
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a

20 µm

b

2 µm
Figure 4.5 Scanning Electron Microscope images of various core-shell PLGA a, b)
Microfibres.
When the polymer concentration reaches 15 wt% for the core and 10 wt% for the shell, only
microfibres (Figure 4.5) are produced.
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Microflakes
d

d
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d

d

Microspheres-fibers

Bead Microfiber

Microfibers

Figure 4.6 Schematic illustration of the detection points of the sizes of the fabricated coreshell microflakes, flattened microspheres, microspheres, microspheres-fibres, beaded
microfibres, and microfibres. The d is from the detection points as shown in figure.

Our work demonstrates the critical roles of both the polymer concentrations of the core and
shell solutions in controlling the shape and morphologies of the electrojetted core-shell
microcapsules. A similar concentration effect has recently been reported in a range of PLGA
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microcapsules that were produced by electrojetting a single solution and thus do not possess
the core-shell structures [31].

In order to evaluate the shape, size and size distribution of the as-prepared microcapsules, a
Leica Application Suite was used to analyse the SEM images. The detection points of the
sizes of the microcapsules are schematically illustrated in Figure 4.6.
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2
5
Solution concentration (wt %)
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Figure 4.7 Size of the core-shell microflakes, flattened microspheres, microspheres,
microspheres-fibres, beaded microfibres, and microfibres.
The sizes of the microflakes, flattened microspheres, microspheres, microspheres-fibres,
beaded microfibres, and microfibres are presented in Figure 4.7. The size distributions of
each kind of microcapsules are shown in Figure 4.8.
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Figure 4.8 Size distribution of each type of core-shell microcapsules.

Each type of the electrojetted core-shell microcapsules exhibits a narrow size distribution and
uniform morphology. With an increase in the PLGA concentrations, the dimension of the
respective microcapsules firstly increased, and then decreased in the case of microfibres. The
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diameters are 2.26±0.67 µm for the microflakes, 2.67±0.46 µm for the flattened
microspheres, 4.42±1.08 µm for the microspheres, 5.35±0.94 µm for the microspheres-fibres,
7.02±1.45 µm for the beaded microfibres, and 1.11±0.43 µm for the microfibres,
respectively.

In accordance with Hartman’s study [37], the dimension of PLGA microspheres formed
using electrospraying is governed by the surface tension of the polymer solution, as shown in
Equation (4.1):

𝑑~(

𝜌𝜀0 𝑄3 1⁄6
)
𝛾𝐾

(4.1)

Where 𝑑 is the droplet size, 𝜌 is the density of solution, 𝜀0 is the permittivity of vacuum, 𝑄 is
the liquid flow rate, 𝛾 is the surface tension of solution in ambient air, and 𝐾 is the liquid
conductivity (International system od units). Increasing the polymer concentration leads to an
increase in the solution viscosity, and a reduction in the surface tension(𝛾), and consequently
an increase in microsphere size (d) (Equation 4.1) [37]. When the polymer concentration
becomes sufficiently high, the solution can endure continuous and longer stretching from the
nozzle tip to the collector, which gives rise to much thinner microfibres through the
mechanism of electrospinning.

4.3.3 Drug encapsulation efficiency
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Figure 4.9 Drug encapsulation efficiency of the core-shell microflakes, flattened
microspheres, microspheres, microspheres-fibres, beaded microfibres, and microfibres.

It is shown in Figure 4.9 that all the fabricated core-shell microcapsules exhibit  90% drug
encapsulation efficiencies. The core-shell microfibres demonstrate the highest drug
encapsulation efficiency (99.2±5.4%). These encapsulation efficiencies are greater than those
prepared using other techniques, including emulsion, suspension, and emulsion
polymerization [38], solvent evaporation [38, 39], spray drying [40], layer-by-layer [41]. This
can be ascribed to i) the inherent core-shell structures where the drug is encapsulated in the
core and further protected by a shell of more hydrophobic polymer and ii) the fast
solidification of the microcapsules at room temperature due to the use of a low boiling point
solvent, chloroform [31, 42].
134

4.3.4 In vitro drug release study
The representative in vitro release profiles of lacosamide from the fabricated PLGA
microflakes, microspheres, microspheres-fibres, and microfibres are shown in Figure 4.10.

Figure 4.10 Cumulative release of lacosamide from the fabricated core-shell PLGA
microcapsules including microflakes, microspheres, microspheres-fibers, and microfibers in
aCSF (pH 7.4) at 37 ℃ over 104 days.
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The sustained release characteristics demonstrated by all the microcapsules could be
attributable to their core-shell structures, where the drug-free polymer shells present an
additional barrier to the drug elution from the core [35]. The release profiles varied
significantly with the shape and morphologies of the microcapsules. The microflakes
exhibited the most rapid release characteristics, with > 96% of the encapsulated lacosamide
being eluted within ~43 hours. Within the same period, the cumulative release of the
lacosamide from the microspheres, microspheres-fibres, and microfibres, was approximately
75%, 60%, and 35% of the respective total drug loading. Compared to the microflakes,
microspheres, and microsphere-fibres, microfibres exhibited significantly less initial burst
release.

Figure 4.11 The release profiles of the core-shell microcapsules including microflakes,
microspheres, microspheres-fibers, and microfibers in the first 20 days.
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It is also noted that there is no significant mass loss in the microcapsules after a prolonged
incubation in aCSF (104 days), other than that arising from the drug elution. This suggests
minimal polymer degradation of the electrojetted microcapsules taking place within this
period, which also indicates that the drug release from these microcapsules is predominantly
diffusion controlled. The morphology and dimension of the PLGA microcapsules had a
significant influence in the lacosamide release characteristics.

Figure 4.12 Comparison of the release profile of the microspheres to that of core-shell
microspheres.
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For the microcapsules with dominant sphere/particulate shape, including microflakes,
microspheres, microspheres-fibres, the release rate decreased with increasing microcapsule
dimension (Figure 4.7 and Figure 4.11). With an increase in the sizes of the microcapsules,
the surface area to volume ratios of the microcapsules decrease, and this leads to slower water
penetration rates into the microcapsules and thus slower drug release profiles. Compared with
the microspheres (Figure 4.12) and microfibres (Figure 4.13) without core-shell structure,
the core-shell structured microspheres and microfibres exhibit significantly slower release.

Figure 4.13 Comparison of the release profile of the microfibres with that of core-shell
microfibres.
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These microcapsules can serve as injectable microparticulate systems or polymer implants,
for the local pharmaceutical intervention of epilepsy, as well as treatments for other
neurological disorders, such as Parkinson’s disease, Huntington’s disease, and Alzheimer’s
disease. Compared with the systemic administration that requires high dosages, local
implantation or injection using these drug-eluting microcapsules can significantly reduce the
dosage and side effects. Moreover, these drug release studies demonstrate that the daily
release dosage of these systems could be readily tailored by varying the shape and size of the
microcapsules.

4.4 Conclusions
In summary, a variety of core-shell structured PLGA microcapsules containing an antiepilepsy drug, lacosamide, have been fabricated by a novel electrojetting technique. These
microcapsules, including microflakes, flattened microspheres, microspheres, microspheresfibres, beaded microfibres, and microfibres, all demonstrated narrow size distribution and
uniform morphology, high efficiency of drug encapsulation and sustained drug release
characteristics. The release profile of lacosamide varies with the morphologies and shape of
the core-shell microcapsules and thus can be readily controlled over long periods of time.
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5. CHAPTER 5: DEVELOPMENT OF
ELECTROSPUN AND
ELECTROSPRAYED DUAL DRUG
DELIVERY MATRICES
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5.1 Introduction
The packaging and delivery of drugs to a specific location in the human body via
biomaterials systems has been approaching the forefront of biomedical research for the past
few decades [1-5]. Most of the drug delivery systems have been developed focusing on the
achievement of mono drug release by developing a wide variety of biomaterial carriers.
However, there are many situations that require multiple medications. Combination therapy
with drugs of different therapeutic effects provides an effective strategy in the treatment of
diseases [6]. Studies also show that combined therapy with two or more drugs provides a
promising strategy to suppress drug resistance as different drugs possess different therapeutic
effects at various pathological stages [7]. A variety of drug combinations can induce
synergism and have shown promise in preventing disease recurrence [8-13].

One major challenge of combination therapy is to ensure effective dose for each drug
independently. In order to overcome this challenge, one of the most popular approaches is to
load multiple therapeutic agents into one delivery system and then concurrently deliver them
to the site of action [8, 12, 14, 15]. A number of such drug delivery systems, including
nanoscale and microscale particles, have been developed, for delivery of multiple drugs.
However, fine control of the dosage and release kinetics remains a challenge. Besides, the
complexity of the materials for use in the human body creates additional regulatory
challenges. In addition, our limited understanding of the interactions between these new
synthesis compounds and the body, especially the diseased part environment presents hurdles
[1, 16]. The complicated fabrication process also makes it difficult to mass produce and apply
it widely to clinical use of the drug delivery systems.
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This chapter aims to use combinatorial electrospinning and electrospraying, to fabricate
composite matrices as dual drug delivery vehicles. The composite structures of fibrous
matrices with microparticles dual drug delivery systems demonstrated well-controlled
internal structures, with uniform morphology and favourable thermal and mechanical
properties. The drug release study shows that the daily dosage and release kinetics of these
systems can be tailored by varying the shape and size of the polymeric carriers. In addition,
the release behaviour of these dual drug delivery systems can be predicted using
mathematical modelling.
5.2 Experimental

5.2.1 Materials
Poly(D,L lactic-co-glycolic acid) (PLGA) with a molar ratio of lactide to glycolide, 75 to 25,
and polylactic acid (PLA), were purchased from Purac, Singapore, and used as received. The
anti-epilepsy drug, lacosamide, was provided by UCB Pharma Pty Ltd. Phenytoin and
dexamethasone were purchased from Sigma-Aldrich. All the others chemicals and reagents
not mentioned above were purchased from Sigma-Aldrich and used as received without
further purification.

5.2.2 Fabrication of Composite matrices
The polymer solutions for electrosprayed spheres were prepared by dissolving PLA and
PLGA separately with the drug in chloroform. And the polymer solution for electrospun
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fibres was prepared by dissolving PLA and drug in chloroform/DMF (volume ratio, 4/1). The
solvent and a mixture solvent of the electrospinning and electrospraying conditions were
optimized to obtain bead-free PLA fibres and uniform spherical PLA, PLGA spheres. In
these solutions, the ratio of polymer/drug (w/w) was kept constant at 10/1, while the polymer
concentration varied from 0.75 to 9.6 wt%. After encapsulation efficiency testing, drug
loadings were achieved, which were 9.72 % for PLA phenytoin microfibres, 9.06 % for
PLGA lacosamide microspheres, 9.35 % for PLA lacosamide microfibres, and 9.10 % for
PLGA dexamethasone microspheres.

Composite dual drug delivery systems were formed by combinatorial electrospinning and
electrospraying from two opposing spinnerets onto a rotating mandrel at room temperature
[17, 18]. The solutions were loaded into plastic syringes with 23-gauge stainless steel needle
independently. For electrospinning microfibres, the injection rate was 0.3 mL/h, the applied
voltage was 21 kV, and the distance from the tip of the needle to collector mandrel was 15
cm. For electrospraying microspheres, the injection rate was 0.5 mL/h, the applied voltage
was 10 kV, and the distance from the tip of the needle to collector mandrel was 12 cm. The
rotation speed of the mandrel was set as 0.2 m/s. The low enough rotation speed can prevent
microfibres alignment [19]. In order to obtain a homogeneous mixture of the microfibres and
the microspheres, a dielectric tap was attached to the rotating mandrel to delimit the
deposition area. The charged electrospraying microspheres are very sensitive to the
electrostatic field and can be confined with a dielectric tap [18]. In order to remove possible
residual organic solvent, all the samples were further dried in a vacuum oven at room
temperature for 48 hours.
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5.2.3 Characterization and evaluation
A Field Emission Scanning Electron Microscope (FESEM, JEOL JSM-7500FA) was used to
examine the morphologies of the as-fabricated microcapsules. Before the SEM examination,
the specimens were sputter-coated with gold to avoid charge accumulation. Dimensional
statistical analysis was conducted by analysis of the SEM micrographs using the imaging
software, Leica Application Suite. All data were expressed as the mean ± standard deviation
(STDEV). Thermogravimetric analyses (TGA) were carried out by using Q500 (TA
Instruments), the heating rate was set at 10 oC/min, and the TGA curves were recorded from
50 to 800 oC under 15 ml/min flow of N2. The amounts of samples for the TGA analyses
were ~ 10 mg to avoid possible thermal lag. For testing the mechanical properties of
composite matrices, the prepared matrices were cut into standard dumbbell-shaped
specimens, and the test was performed by using a commercial mechanical Shimadzu EZ-L
testing machine at the crosshead speed of 5 mm/min. Five specimens were tested for each
sample, and the average values with respective standard deviations were calculated.

5.2.4 In vitro drug release study and quantification of drug encapsulation efficiency
In vitro drug release was conducted in artificial cerebrospinal fluid (aCSF) at 37 oC in a
shaking water bath. At appropriate sample time, the release medium was withdrawn and
replaced with equal amount of fresh aCSF. The released samples were analysed using the
HPLC to determine the amounts of drug released.

HPLC analysis was conducted using an Agilent 1260 Infinity HPLC system. The analytical
column used was an Atlantis® T3 C18 column (5 µm, 250 mm × 4.60 mm). The testing
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parameters for the three drugs are summarised in Table 5.1. The amounts of released drug
were calculated according to a pre-established calibration curve in aCSF [20-22]. The drug
encapsulation efficiency was determined by using an extraction method according to our
previous work [17]. Briefly, each sample (1 cm × 1 cm) was placed into 1 mL methanol for
12 hours, after which the methanol was removed and replenished with 1 mL of fresh
methanol. This extraction procedure was repeated four times, with each methanol sample
being allowed to evaporate to leave the residual drug behind, which was reconstituted using
aCSF. The drug content was then analysed using HPLC as described above.

Table 5.1 HPLC testing parameters for the drugs including mobile phase, UV-Vis detection
wavelength, and mobile phase flow rate.
Name of drug

Lacosamide

Mobile phase (v to v)

Milli-Q water, acetonitrile, and

Detection

Flow rate

wavelength (nm)

(mL/min)

210

0.8

methanol (65:26.2:8.8)
Phenytoin

Milli-Q water and acetonitrile (50:50)

203

1.4

Dexamethasone

Milli-Q water and acetonitrile (35:65)

242

1.0

with 0.1 % trifluoroacetic acid
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5.3 Results and Discussion
5.3.1 Fabrication and selection of proper component
The process parameters including choosing of polymer, preparation of the solution,
conditions of electrospinning and electrospraying et al. were optimized in order to achieve
steady and repeatable formation of beaded-free microfibres and proper spherical
microparticles.

a

b

20 µm

2 µm

Figure 5.1 Scanning electron microscope images of electrosprayed PLA erythrocyte-like
microspheres.

As discussed in chapter 3, the electrojetted polymeric structures mainly depend on the
polymer concentration and electrojetting parameters. Here, the focus is on discussion of the
fabrication of PLA microspheres and microfibres. Similarly, by adjusting the polymer
concentration and electrospraying parameters, erythrocyte-like PLA microspheres (Figure
5.1) were obtained. They were prepared using a polymer concentration of 0.75 wt%. All these
erythrocyte-like PLA microspheres demonstrated narrow size distribution and uniform
morphology. As the PLA concentration increased to 2 wt%, two kinds of microspheres, PLA
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microspheres (Figure 5.2b), beaded microspheres (Figure 5.2c) with a certain amount of
concomitant nanofibre were fabricated. It indicates that higher polymer concentrations tend to
form fibres.

a

20 µm

b

c

2 µm

2 µm

Figure 5.2 Scanning electron microscope images of electrosprayed PLA microfibres with
two kinds of PLA microspheres, b) microspheres and c) beaded microspheres.

On further increase of PLA concentration to 4.5 wt%, PLA beaded microfibres appeared
(Figure 5.3 a,b). This phenomenon agrees with former chapters’ studies, and there is a
transition stage between spherical structures and fibrous structures. Finally, when the
polymer concentration was eventually increased to 9.6 wt%, the microfibres were formed, as
shown in Figure 5.3 c,d.
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b

a

2 µm

20 µm

c

d

20 µm

Figure 5.3

2 µm

Scanning electron microscope images of electrosprayed PLA a,b) beaded

microfibre and c,d) microfibres.

Both PLA and PLGA have been widely accepted for use in medical devices due to their
excellent biocompatibility. The PLA and PLGA materials also exhibit low toxicity and
immunogenicity, as well as well-defined biodegradation. Compared with PLGA, the absence
of glycolic acid segments makes PLA more hydrophobic and results in longer degradation
kinetics. Therefore, electrospun PLA was chosen rather than PLGA as a fibrous carrier in the
composite matrices.
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a

b

20 µm

c

2 µm

d

20 µm

2 µm

Figure 5.4 Scanning electron microscope images of electrosprayed a,b) PLGA flattened
microspheres, c,d) PLGA microspheres.

Firstly, erythrocyte-like PLA microspheres were used as a spherical component.
Unfortunately, it was found that the erythrocyte-like PLA microspheres could not tightly
incorporate into the PLA microfibres matrices. Part of the erythrocyte-like PLA microspheres
even dropped out from the composites matrices when it was incubating in the release medium
aCSF. Then, as discussed in former chapters, flattened PLGA microspheres (3.5 wt%, Figure
5.4 a,b) and PLGA microspheres (4.5 wt%, Figure 5.4 c,d) were also tried as the spherical
component. The outcome was that the Flattened PLGA microspheres could be firmly
attached to the PLA microfibres. The mechanism and more detailed information are
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discussed and given below. All microcapsules with various polymers, structure, and their
respective fabrication conditions are summarized in Table 5.2.

Table 5.2 Microcapsules with various polymers, structure, and their respective fabrication
conditions.
Polymers

PLA

Solution

Applied Voltage

concentrations (wt%)

(kV)

0.75

10

Structure Type

Erythrocyte-like
microspheres

PLA

2.0

10

Microspheres, beaded
spheres, and fibres

PLA

4.5

21

Beaded microfibres

PLA

9.6

21

Microfibres

PLGA

3.5

10

Microspheres

PLGA

4.5

10

Flattened microspheres
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5.3.2 Fabrication of composite matrices containing two types of drugs

Power source

Rolling drum
Power source
kV

kV

+++
++
+
++++

+++
++
+
+
+
+
+
Stable Taylor Cone

Unstable Taylor Cone

PLGA Solution

PLA Solution

Syringe and Pump

Sphere Formation

Fiber Formation

Drug 1

Syringe and Pump

Drug 2

20 µm

PLA

PLGA(75/25)

Figure 5.5 Schematic of the fabrication process of dual drug delivery composite matrices by
using combinatorial electrospinning and electrospraying; the stable Taylor core of PLA
solution (containing phenytoin or lacosamide) tend to form microfibres, and the unstable
Taylor core of PLGA solution (containing lacosamide or dexamethasone) tend to form
microspheres.

Figure 5.5 shows the schematic fabrication process of composite matrices as dual drug
delivery systems. In order to minimize the charge effect between electrospinning and
electrospraying, PLGA microspheres were electrosprayed on one side of the rotation
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mandrel, and PLA microfibres were electrospun on the other side, to generate the composite
matrices.

Different from electrospinning, the Taylor core (as shown in Figure 5.5) is unstable in the
electrospraying process, and the liquid jet is destabilized due to varicose instability, and
hence fine droplets were formed [24].

a

20 µm

b

2 µm

Figure 5.6 Scanning electron microscope images of PLA phenytoin microfibres/ PLGA
lacosamide microspheres composite matrices; fewer microspheres indicate lower drug ratio.
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While the drops move from the needle tip to the rotating mandrel, rapid solvent evaporation
and polymer diffusion occurs. This leads to the formation of spherical microparticles. When a
low concentration of PLGA, such as 3.5 wt%, was used in this work, flattened microspheres
were formed. This is due to incomplete solvent evaporation, and, therefore, the
electrosprayed microcapsules are still partially dissolved when they reach the surface of the
PLA microfibres. Before hitting the surface of the PLA microfibres, there is still a small
amount of residual solvent in the PLGA microspheres; which makes the microspheres deform
and flatten, and firmly attaching to the microfibre to form a conglutinated stable composite
matrix structure [23]. When PLGA microspheres were electrosprayed in combination with
PLA microfibres, a relatively uniform distribution within the microfibres was observed
(Figure 5.6 and 5.7). This results in the formation of composite matrices with randomly
deposited microspheres and microfibres.

As a proof of combined therapeutic conception, two composite matrices were fabricated.
They contain different drugs: PLA phenytoin microfibres/PLGA lacosamide microspheres
composite matrices and PLA lacosamide microfibres/PLGA dexamethasone microspheres
composite matrices. In order to tailor the dosage ratio of two drugs in each composite matrix,
the quantity of PLGA microspheres was roughly controlled by simply varying the duration of
the electrospinning and the electrospraying. As a result, PLA phenytoin microfibres were
incorporated with fewer PLGA lacosamide microspheres, and PLA lacosamide microfibres
were incorporated with more PLGA dexamethasone microspheres. The SEM images (Figure
5.6 and 5.7) clearly show this quantitative difference of the two kinds of PLGA microspheres.
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a

20 µm

b

2 µm

Figure 5.7 Scanning electron microscope images of PLA lacosamide microfibres/ PLGA
dexamethasone microspheres composite matrices, more microspheres indicate higher drug
ratio.
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5.3.3 Thermal properties of composite matrices
Thermogravimetric analysis (TGA) curves of the PLA microfibres, PLA-phenytoin
microfibres/PLGA-lacosamide

microspheres

composites,

PLA-lacosamide

microfibres/PLGA-dexamethasone microspheres composites and PLGA microspheres are
presented in Figure 5.8.
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Figure 5.8 Thermogravimetric analyses (TGA) results of the as-fabricated
PLGA microspheres, PLA microfibres matrices and composite matrices
which contain drugs.

The initial weight loss found up to 120 oC is probably attributable to the physical loss of
moisture. It indicates that the weight loss at this stage is not related to polymer thermal
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decomposition. [24]. All samples demonstrated sharp mass loss between ~240 oC to ~380oC,
and this is attributed to the decomposition of the polymer chains [25]. Without the drug, both
PLA microfibres and PLGA microspheres showed nearly zero residues. However, the
composite matrices demonstrated higher carbon residues. This may be ascribed to the
aromatic ring structure of the model drugs. In addition, evidence for drug encapsulation is
also afforded by these TGA plots which are shown above.

5.3.4 Mechanical properties of the composite matrices
For drug delivery systems, mechanical properties are important since deformation or fracture
in the implanted device will significantly affect the drug release kinetics [26].

Table 5.3 Mechanical properties of electrospun PLA microfibre and the composite matrices.
Sample

Tensile strength

Tensile modulus

Strain at break

(MPa)

(MPa)

(%)

PLA fibres

4.6±0.81

97±7.6

98±1.4

PLA phenytoin /PLGA

6.0±0.46

172±42

62.3±8.1

2.8±0.21

66±13

76±5.7

lacosamide

PLA lacosamide /PLGA
dexamethasone
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The typical stress-strain curves acquired from PLA microfibres matrices, PLA phenytoin
microfibres/PLGA lacosamide microspheres composite matrices, and PLA lacosamide
microfibres/PLGA dexamethasone microspheres composite matrices are shown in Figure 5.9
and summarized in Table 5.3.

8
PLA Fiber
PLA Phenytoin-PLGA Lacosamide
PLA Lacosamide-PLGA Dexamethasone

7

Stress (MPa)

6
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20

40
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80

100

120

Strain (%)
Figure 5.9 Typical tensile stress-strain results of as-fabricated PLA microfibres
matrices and composite matrices which contain drugs.

All PLA microfibres matrices and composite matrices demonstrated high tensile strength, as
well as high tensile modulus. The favourable mechanical properties can be ascribed to the
high molecular orientation along the PLA microfibres axes [27]. During the formation of
microfibres, the liquid jet undergoes a whipping or bending motion process, which is very
fast and leads to the rapid drawing of the molecular chain among the microfibres. The tensile
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strength of the PLA fibres matrices is 4.6±0.81 MPa, slightly increased to 6.0±0.46 MPa for
PLA phenytoin/PLGA lacosamide composite matrices (fibres with fewer spheres), then
slightly decreased to 2.8±0.21 MPa for PLA lacosamide/PLGA dexamethasone composite
matrices (fibres with more spheres). While, the modulus initially increased from 97±7.6 MPa
to 172±42 MPa, and then decreased to 66±13 MPa. With increasing numbers, microspheres
cannot be distributed uniformly. Instead, they formed small partial spherical accumulations,
and these accumulations became structural defects in the composite matrices. When the
composite matrices are under tensile testing, the defects made them fracture easily [28,
29].5.3.5 In vitro drug release study and mathematical simulation

Figure 5.10 Drug encapsulation efficiency testing results of PLA fibres and PLGA spheres in
composite matrices.
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5.3.5 In vitro drug release study and mathematical simulation
Drug encapsulation efficiency is an important index for drug delivery systems, especially for
rare and expensive drugs. A suitable microencapsulation technique should result in high
encapsulation efficiency[30]. Drug encapsulation efficiency testing was conducted by using
an extraction method. As shown in Figure 5.10, all microfibres and microspheres
demonstrated high drug encapsulation efficiency. They were 97.2±3.7% for PLA phenytoin
microfibres, 90.6±10.3% for PLGA lacosamide microspheres, 93.5±4.6% for PLA
lacosamide microfibres, 91.0± 7.2% for PLGA dexamethasone microspheres. The total
encapsulation content of two kinds of drugs in each microsphere was also detected by the
extraction method. Composite matrices with more microspheres contained fivefold higher
molar ratio of drug than those with fewer microspheres; of relative composite matrices.
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Figure 5.11 Cumulative release of each drug from PLA phenytoin microfibres-PLGA
lacosamide microspheres composite matrices.

In general, drugs which were encapsulated in microspheres were released faster than those
encapsulated in microfibres. PLGA lacosamide microspheres exhibited rapid release, ~62%
of total lacosamide within 24 hours, and ~96% within 220 hours. While PLA phenytoin
microfibres just released ~16% of total phenytoin within 24 hours, followed by a slower
release of up to 45% within 220 hours. The release rates of PLA lacosamide microfibres and
PLGA dexamethasone microspheres were not so obviously different, but it still exhibited
independent release characteristics. The entire release rates were with an initial burst, then
with a long slower period. As the composite matrices were placed in aCSF medium, water
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rapidly penetrated into the exposed surface of microspheres and microfibres, and the drugs
trapped within a thin surface layer were quickly released. Subsequently, it took a longer time
for water to diffuse in and the drugs to diffuse out, thus limiting the later drug release rates
[31].

Figure 5.12 Cumulative release of each drug from PLA lacosamide microfibre/PLGA
dexamethasone microspheres composite matrices.

As shown in in vitro drug release testing, the release profiles of the drugs vary with the
morphology and shape dimension of the microfibres and microspheres. In order to evaluate
the effects of morphology, shape dimension, and develop a capability for predicting the
kinetics of drugs release of the microfibres and microspheres, a theoretical analysis of time167

dependent diffusion with an initially uniform drug concentration was performed. For
mathematical simulation of microspheres and microfibres, a drug release profile is obtained
by solving Fick’s second law as described in chapter 3. The fraction of the initial drug
loading released from the microcapsules (Mt/M∞) at any time (t) can be expressed by
equation 3.1 given in chapter 3 as follows:

∞
M𝑡
𝑀∞

=1−∑
𝑛=0

2𝑖
𝜆𝑛 2

𝑒

−

4𝜆𝑛 2 𝐷𝑒 𝑡
𝑑2

(3.1)

Figure 5.13 Dimensional statistical analysis results of diameters including PLA phenytoin
fibres, PLGA lacosamide spheres, PLA lacosamide fibres, PLGA dexamethasone spheres.
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The diameters of the microfibres and microspheres are assessed by analyzing the SEM
images, and the results are shown in Figure 5.13. The diameters are 1.19±0.34 µm for PLA
phenytoin microfibres, 5.57±1.15 µm for PLGA lacosamide microspheres, 1.22±0.37 µm for
PLA lacosamide microfibres, and 4.63± 0.68 µm for PLGA dexamethasone microspheres.
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Figure 5.14 Diameters distribution of PLA phenytoin microfibres, PLGA lacosamide
microspheres, PLA lacosamide microfibre, and PLGA dexamethasone microspheres.
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Moreover, as shown in Figure 5.14, all the microfibres and microspheres of the composite
matrices exhibit narrow size distribution and uniform morphology. The mathematical
modelling study is based on the equation (3.1) and using MATLAB Curve Fitting Toolbox.

Figure 5.15 Mathematical modelling of drug release of PLA penytoin fibres and PLGA
lacosamide spheres (solid curves: theory fitting results, symbols and standard deviations:
experimental sampling points).

The effective diffusivities of drugs are used as a least-squares fitting parameter, as shown in
Figure 5.15 and Figure 5.16, the theoretical predictions from the mathematical modelling
are in agreement with the experimental cumulative release data . It indicates that drug release
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from the microfibres and microspheres of these composite matrices can be satisfactorily
described as a time-dependent diffusion process [31]. The computed effective diffusivities are
1.49×10-14 cm2/min for PLA phenytoin microfibres, 1.48×10-12 cm2/min for PLGA
lacosamide microspheres, 9.62×10-14 cm2/min for PLA lacosamide microfibres, and 2.03×1012

cm2/min for PLGA dexamethasone microspheres. This is the reason why microspheres

exhibit significantly faster release kinetics than those of microfibres.

Figure 5.16 Mathematical modelling of drug release of PLA lacosamide fibres and PLGA
dexamethasone spheres.
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5.4 Conclusions
Overall, this study considered the use of a combinatorial electrospinning and electrospraying
system to fabricate PLA microfibres/ PLGA microspheres composite matrices for dual drug
delivery. The as-fabricated composite matrices showed favorable thermal and mechanical
properties. And the microfibres and microspheres of the composite matrices demonstrated
narrow size distribution, uniform morphology, and high efficiency of drug encapsulation.
Independently controlled release behaviours are achieved in these dual drug delivery
composite matrices. And the dosage ratio of different drugs in composite matrices could be
tailored by simply varying the electrospinning and electrospraying time. The release profiles
are fit well with the mathematical simulation model. This result indicates that the release
kinetics is predictable. A similar strategy could be introduced to other dual drug release
systems to provide a wide range of biomedical applications such as growth factor for cell
culture or tissue engineering.
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6. CHAPTER 6: CONDUCTING AND
BIODEGRADABLE POLYMERS
COMBINED 3-DIMENSIONAL
ELECTRODES DELIVERY SYSTEMS
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6.1 Introduction
Conducting polymers (CPs) have received considerable interest in recent decades for their
unique and tunable physical and chemical properties [1-5]. Their attractive electrical, optical,
mechanical, and interfacial properties are derived from their conjugated π-electron system.
CPs have been investigated for numerous biomedical applications, including electrically
controlled release [6-9], tissue engineering [10, 11] [12], neural prosthesis [13, 14], biosensors [15], and bio-actuators [16, 17] et al. . In these applications, polypyrrole (PPy) and
poly(3,4-ethylenedioxythiophene) (PEDOT) are popular candidates because of their chemical
stability, superior conductivity, and biocompatibility. Moreover, they can be readily prepared
by chemical or electrochemical means [4]. During the course of preparation, appropriately
sized biomolecules and drugs can be incorporated into the polymer matrices. In addition,
these polymers exhibit low electrochemical impedance, and this facilitates controlled release
of the entrapped bioactive molecules via electrical stimulation [6].

To date, most of the CPs based electrical stimuli drug delivery systems have been limited to
2D configurations [7, 18]. However, many clinical applications in drug delivery require more
sophisticated structures in three dimensions, in addition to biocompatibility and excellent
mechanical properties[19]. It is a huge challenge to progress towards 3D electroactive
delivery systems with well-controlled internal structures, because of their poor processability
(poor solubility in solvents and inability to directly melt process) of CPs. What’s more, free
standing films of CPs tend to be brittle，inflexible and have poor conductivity. To overcome
these drawbacks, attention has been given to developing CP coatings on prefabricated 3D
electrode systems[7].
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Recently, additive manufacturing, also known as 3D printing, has shown great promise as a
novel technology for fabrication of 3D constructs with sophisticated internal structures. 3D
printing involves layer-by-layer deposition of materials, which is controlled digitally, and
thus can deliver complex, personalized and on-demand products. More recently, 3D printing
has attracted increasing interest in pharmaceutical manufacturing. Progress has resulted in the
Food and Drug Administration (FDA) approval of 3D printed drug products from August
2015 [20, 21].
Selective laser melting (SLM) is a popular 3D printing process to fabricate metal products
[22]. During the SLM process, the laser beam selectively melts successive layers of metallic
powder. Upon irradiation, the powder melts and forms a liquid pool. Then, it solidifies
quickly to form 3D structures according to a 3D Computer-aided design (CAD) volume
model. Being able to design and create geometrically complex metallic objects, it could be
interesting for the application of SLM products in CPs drug delivery systems.

In previous chapters, a set of biodegradable microcapsules including microspheres and
microfibres have been developed. Moreover, composite membranes composed of these
microcapsules also have been fabricated as dual drug delivery systems that can be used for
combination therapy. In this chapter, an attempt at the application of these biodegradable
microcapsules in 3D printed electrodes is considered. The attempt also aims to explore the
way to continue development of dual drug delivery systems for combination therapy.
Fortunately, the 3D printed electrodes based on the interdigitated structures offer the
possibility of combining these biodegradable microcapsules with CPs in the third dimension
[23].
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This chapter aims to demonstrate a new 3D system for the controlled release of antiepileptic
drugs by electrical stimulation. 3D printed (selective laser melting) interdigitated Ti 6Al4V
electrodes serve as the structural support for the electropolymerized outer layer of
polypyrrole (PPy). Fosphenytoin is an anti-epilepsy prodrug (AED) and is used as the dopant
for the preparation of the 3D PPy coating. The release of fosphenytoin in artificial
cerebrospinal fluid (aCSF) from the 3D drug delivery system is controlled by switching the
redox state of PPy. Moreover, combined with biodegradable microspheres which contain
dexamethasone (independently coated on the electrode), two interdigitated electrodes can
serve as a multi-functional drug delivery system. The electrical conductivity, biocompatibility
and tuneable release properties of the 3D printed drug delivery system can also lead to
promising localized treatment of other central nervous system diseases.

6.2 Experimental

6.2.1 Materials
Ti-6Al-4V powder was from TLS Technik Spezialpulver. Pyrrole monomer was from Merck
and was freshly distilled before use. Poly(D,L lactic-co-glycolic acid) (PLGA) (Mw ~ 60,000
Da, molar ratio of lactide to glycolide, 75 to 25) was purchased from Purac, Singapore.
Fosphenytoin and dexamethasone were purchased from Sigma-Aldrich, and used as received.
All the others chemicals and reagents were purchased from Sigma-Aldrich and used as
received without further purification.
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6.2.2 3D printing of interdigitated electrodes
The 3D interdigitated electrodes were designed using SolidWorks modelling software. After
that, the electrodes were printed by using a Realizer SLM50 metal printer (Germany). The
printer is based on the additive manufacturing technology which is called Selective Laser
Melting (SLM). Before printing, the printer’s chamber is evacuated and then filled with an
inert argon atmosphere. The high-powered laser beam of the printer focused on a bed of fine
Ti-6Al-4V powder. The laser selectively fuses the particles in a layer-by-layer fashion. All
untouched powder remains as it is and becomes a support structure for the electrode.

6.2.3 3D coating of fosphenytoin loaded conducting film
Milli-Q water and ethanol were used to clean the 3D printed Ti alloy electrodes. A solution
containing 0.2 M pyrrole monomer and 0.02 M fosphenytoin was prepared in Milli-Q water.
Electrochemical polymerization was carried out using a CHI 600 (CH Instruments) at a
constant potential of 0.8 V for 20 mins at room temperature. The applied reference electrode
was silver/silver chloride reference electrode, and the counter electrode was stainless steel
mesh. The electrodes were rinsed with a Milli-Q water/ethanol mixture in order to remove
any residual fos-phenytoin, pyrrole, and oligomers on the surface. Then, the electrodes were
dried in a vacuum oven at room temperature for 24 hours.

6.2.4 Electrospray coating of PLGA dexamethasone microspheres on the 3D electrodes
PLGA was dissolved in chloroform at 4 wt.%; subsequently, dexamethasone was added into
the PLGA solution to obtain the electrospraying solution (PLGA:dexamethasone, 10:1). After
encapsulation efficiency testing, a drug loading of 9.35 % was achieved. The solution was
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held in a syringe with a stainless steel needle having an orifice of 0.34 mm. The needle was
electrically connected to a positive high voltage power supply of NANON-01A electrojetting
systems (MECC Co. Ltd, Japan). Electrospraying was carried out in the electrojetting
systems’ chamber at room temperature. During the electrospraying process, a positive high
voltage of 10 kV was applied to the needle, and the solution flow rate of 0.5 mL/h was
maintained by using a syringe pump. Electrosprayed PLGA/dexamethasone microspheres
were collected on the surface of the 3D printed electrodes. After that, the electrodes were
held at room temperature for 48 hours in a fume hood to allow completion of the residual
solvent evaporation.

6.2.5 Scanning electron microscope
The morphology characterization was performed by JEOL JSM-7500FA scanning electron
microscope (SEM) with field emission gun (FEG). For conductive Ti alloy electrodes and
polypyrrole, SEM testing was conducted directly without sputter-coating. Non-conductive
PLGA microspheres were sputter-coated with 20 nm gold before SEM testing.

6.2.6 Electrochemical measurements
Electrochemical impedance spectroscopy (EIS) was measured using a Gamry EIS 3000

TM

system with Gamry framework software using a three-electrode system. The frequency range
was from 0.1 Hz to 100 kHz, and the AC perturbation was 5 mV at open circuit potential.
Cyclic voltammetry (CV) was carried out in a three-electrode system with a Pt counter
electrode and Ag/AgCl reference electrode by using a CHI 600 (CH Instruments) apparatus.
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A scan rate of 100 mV/s was used, and the potential applied was swept between -1.0 and 0.5
V.

6.2.7 In vitro electrically controlled drug release
Electrically controlled drug release experiments were carried out in a three-electrode
electrochemical cell using artificial cerebrospinal fluid (aCSF) as the release medium. A
square wave, biphasic voltage stimulation was used for electrically stimulating drug release.
The applied negative potentials were -1 V, -0.5 V, and -0.25 V, respectively, and the positive
potential was 0.5 V. Each square wave (cycle) of the electrical stimulation was a 50% duty
cycle; 5 seconds of negative potential and 5 seconds of positive potential. Every 30 cycles
(or more) of square wave electrical stimulation, the release medium was collected and
replenished with fresh aCSF. For comparison, passive drug release study was also conducted
without electrical stimulation.

6.2.8 PLGA microsphere diametric statistics and drug release study
Diametric statistics was conducted by analysis of the high magnification SEM micrographs
using the imaging software, Leica Application Suite. Drug release study was conducted in
aCSF. The electrodes with PLGA microsphere were directly immersed in a certain amount of
aCSF. All the samples were incubated in a shaking water bath at a constant temperature of 37
o

C. The release media was replaced with the same amount of fresh aCSF periodically. An

extraction method was used to evaluate the drug encapsulation efficiency of the microsphere
as described in our previous work [24]. In order to predict the release profile of
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dexamethasone from the electrosprayed coating, the mathematical analysis was conducted
based on a time-dependent diffusion model and using MATLAB Curve Fitting Toolbox.

6.2.9 Determination of the amount of released fosphenytoin and dexamethasone
Both the amounts of fosphenytoin and dexamethasone were determined by HPLC, using an
Agilent 1260 Infinity HPLC system. The analytical column was Atlantis® T3 C18 column (5
µm, 250 mm × 4.60 mm). For fos-phenytoin testing, the mobile phase consisted of 35% (v/v)
methanol and 65% (v/v) of Milli-Q water. The pH was adjusted to ~3.8 with orthophosphoric
acid; the flow rate was 1 mL/min; the wavelength of UV was 210 nm. For dexamethasone
testing, the mobile phase consisted of Milli-Q water and acetonitrile (35:65, v/v) with 0.1 %
trifluoroacetic acid (v/v); the flow rate was 1.0 mL/min; UV detection wavelength was set at
242 nm. The amounts of the released drug were calculated according to a pre-established
calibration curve.

6.3 Results and Discussion

6.3.1 Fabrication and assembly of the interdigitated 3D electrodes
The 3D interdigitated electrodes were designed and printed by using selective laser melting
(SLM). As shown in Figure 6.1a, electropolymerization was used to deposit a film of PPy
and fosphenytoin on the surface of the 3D electrodes. In the solution containing dopant, the
pyrrole monomers became electrically oxidized and underwent polymerization. During
polymerization, the polymer backbone was positively charged, and the anionic dopant
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molecule was incorporated to maintain charge neutrality [25]. In this study, the dopant was
fosphenytoin, which is a water-soluble phenytoin prodrug and can be converted into the
active form, namely phenytoin. It is often used in the acute treatment of epilepsy [26].

a

Fos-phenytoin

Polypyrrole

b

Poly(lactic-co-glycolic acide)

Dexamethasone

Figure 6.1 Schematic illustration of the fabrication procedures of a) electropolymerization of
PPy fos-phenytoin on the 3D printed electrodes; b) electrosprayed PLGA microspheres
coating on 3D electrodes.

In order to incorporate the non-anionic drug into the printed 3D electrodes drug delivery
system, PLGA microspheres were fabricated by electrospray as drug carrier and coated on the
surface of the electrodes (Figure 6.1b). Dexamethasone was used as a model drug because of
its wide application in anti-inflammatory uses and is an immunosuppressant [27]. Our
electrodes drug delivery system is aimed at local implantation for treatment of epilepsy,
therefore, inflammation and immune response may be inevitable [28]. Dexamethasone loaded
PLGA microspheres coated 3D electrodes were prepared using electrospraying of PLGA186

dexamethasone chloroform solution and coating on the surface of the posts of the 3D
electrode. Several parameters including the concentration of PLGA, solution feed rate, and
applied voltage were tested in order to obtain appropriate microspheres. It was observed that
the as-fabricated microspheres could attach firmly, not just with each other, but also on the
surface of the electrodes. This is probably due to incomplete solvent evaporation when the
PLGA microspheres were reaching onto the electrode collector [29].

a

Assembly on insulated base

b

Assembly on insulated base

Figure 6.2 Schematic of fabrication procedures of a) assembly process of two interdigitated
PPy fos-phenytoin coated electrodes; b) assembly process of interdigitated PPy fos-phenytoin
coated electrode and electrospray PLGA microspheres coated 3D electrode on insulated base.

Figure 6.2 shows the interdigitated electrodes device assembly process. After
electropolymerization or electrospraying, two halves of the interdigitated electrodes were
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assembled on their insulated bases and served as alternating working and counter electrodes
when subject to biphasic square wave electrical stimulation. This interdigitated structure
combined them together and afforded more materials loading within the same dimension
[30]. Furthermore, the size of the posts in these electrodes could be reduced to further
increase the total materials loading. What’s more, the size of the 3D electrode drug release
device could be adjusted, depending on the particular application.

6.3.2 Scanning Electron Microscopy
The electrodes used in this study were 1 cm by 1cm by 1 cm and contain 54 posts. Each post
had a ~500 µm diameter and 8 mm height. The High magnification SEM image shows that
there are many partially welded metal particles distributed on the surface of the post (Figure
6.3a,b).
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Figure 6.3 Scanning Electron Microscopy images of a,b) a whole 3D electrode and
individual post; c,d) high magnification of the bare 3D electrode.
This

provides

an

enhanced

surface

area

for

the

electropolymerization.

After

electropolymerization, the smooth metal surface (Figure 6.3c,d) is covered by a layer of PPy
fos-phenytoin film with cauliflower morphology (higher magnification of Figure 6.4b).
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a

10 µm

b

2 µm

Figure 6.4 Scanning Electron Microscopy images of the PPy-fosphenytoin coating.

The dexamethasone loaded PLGA microspheres are coated on another electrode rather than
on the same electrode with PPy-fosphenytoin. This aims to minimise the interaction of the
drug release. As shown in Figure 6.5, it is noted that there are many gaps between the
microspheres, which enhances the PLGA microsphere coated 3D electrode’s contact with the
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release media. The release media penetrates into the microsphere coating then contacts the
surface of the electrode.

a

10 µm

b

2 µm

Figure 6.5 Scanning Electron Microscopy images of electrosprayed PLGA dexamethasone
coated 3D electrode. The arrows are pointing to the gaps between the microspheres.
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6.3.3 Electrochemical impedance spectroscopy
The electrical properties of the 3D electrodes were tested using electrochemical impedance
spectroscopy (EIS) and cyclic voltammetry. EIS was used to assess the conductivity of the
bare electrode, PPy coated electrode and PLGA microsphere-coated electrode over the
frequency from 1 Hz to 100 kHz (Figure 6.6).

Impedance (Ohm)

104
Bare 3D electrode
PLGA 3D electrode
PPy 3D electrode

103

102

101

100
10-1

100

101

102

103

104

105

Frequency (Hz)

Figure 6.6 The electrochemical testing results of Impedance spectra for bare

3D electrode, PLGA dexamethasone microspheres coated 3D electrode, and
PPy fos-phenytoin modified 3D electrode.
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The impedance of the bare electrode was from ~5.34 kΩ to ~18 Ω. After PLGA microspheres
were coated on the surface, the impedance across all frequencies was increased, from ~6.28
kΩ to ~29 Ω. However, the impedance initially significantly decreased and then slowly
decreased after deposition of the PPy, from ~360 Ω to 16 Ω. In the study here, the impedance
at 1 kHz is particularly important. Since it corresponds to the characteristic frequency of
neuronal action potentials [6, 31]. For the bare electrode, the impedance at 1 kHz was ~16 Ω;
it was increased to ~36 Ω for the PLGA microsphere-coated electrode but was decreased to
~12 Ω for the PPy-coated electrode. These indicate that the PLGA microspheres diminish the
capacitance, while PPy coating improves the capacitance of the electrode interface. However,
the modifications are not dramatic at this frequency.

6.3.4 Cyclic Voltammetry
Cyclic Voltammetry (CV) provides information about the intrinsic redox behaviour of the
electrode materials (Figure 6.7). CV analysis results showed that both the bare electrode and
PLGA microsphere-coated electrode demonstrated negligible charge-storage capacity
compared with the PPy-coated electrode. The charge-storage capacity was calculated from
the integrated area of the CV curves. The CV curve of the PPy-coated electrode exhibits a
reduction peak at -0.71 V and an oxidation peak at -0.06 V. The reduction peak due to the
anionic fos-phenytoin molecules leave the PPy film as a consequence of the negative
potential sweeping. And the oxidation peak is related to re-doping of small ions in the testing
media [7]. The huge reduction peak of the PPy coated electrode indicates a large amount of
drug leaving the PPy film [32]. Also, with a lower impedance of the PPy coated electrode,
more current will pass through the PPy film under a particular voltage pulse. It also shows
that more efficient drug release would be obtained.

193

10
Bare 3D electrode
PLGA 3D electrode
PPy 3D electrode

Current (mA)

5

0

-5

-10
-1.2

-0.8

-0.4

0.0

0.4

0.8

Potential (V)
Figure 6.7 Cyclic voltammograms of the bare 3D electrode, PLGA dexamethasone
microspheres coated 3D electrode, and PPy fos-phenytoin modified 3D electrode.

6.3.5 Electrically controlled release of fosphenytoin
The electrically controlled release performance of the PPy coated 3D electrodes was studied
in aCSF solution by applying voltage pulses. The amount of released fosphenytoin was
determined by HPLC. The electrically triggered release possibly involves a synergistic
process of electrochemical reduction/oxidation and electrically driven movement of charged
molecules. In this study, anionic fos-phenytoin molecules were incorporated into the PPy
coating [6, 32, 33]. When the PPy coating is electrochemically reduced, the fosphenytoin
molecules will be released. The release of the drug is associated with the change of the

194

overall net charge along the PPy backbone in the oxidized form. The drug released during the
reduction process [33].
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Figure 6.8 Electrically controlled fos-phenytoin release: a) cumulative release profile
using repeated square wave, biphasic voltage stimulation (-1 V for 5s, followed by 0
V for 5s) to determine the total available drug.

To evaluate the maximum amount of fosphenytoin released from the PPy coating, an
aggressive, biphasic voltage pulse (-1 V for 5s, followed by 0 V for 5s) was used as
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stimulation until no obvious drug release could be detected (~1400 stimulations). The drug
release curve in Figure 6.8 shows a plateau after ~750 stimulations, after which no
significant amount of drug release was detected.
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Figure 6.9 Cumulative release profiles in response to milder electrical square
wave, biphasic voltage stimulation (-0.5 V for 5s, followed by 0.5 V for 5s), and
without electrical stimulation.

Upon milder electrical stimulation (-0.5 V for 5s, followed by 0.5 V for 5s), a near-linear
drug release profile is obtained (Figure 6.9). Without stimulation, there was no detection of
any significant amounts of drug eluted from the 3D electrode. This is consistent with others’
196

observation, which suggests that this system under consideration is capable of true
electrically controlled release property [32]. In order to demonstrate the flexibility in dosage
control, further drug release studies under different voltage (x) biphasic stimulations (x V for
5s, followed by 0.5 V for 5s) up to 120, where the negative phase (x) was varied from -0.25
to -1 V, the positive phase was 0.5 V were performed. The released amount of drug increased
with increasing negative voltage, from 13.1±5.2 µg to 54.9±5.8 µg (Figure 6.10).
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Figure 6.10 Release amount under 120 cycles of different square wave, biphasic voltage
stimulation, where the negative phase is -0.25, -0.5, -1 V, positive phase is 0.5 V.
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Compared with the single half-electrode, the cumulative amount of released drug from two
interdigitated electrodes was 276±25.3 µg , an increase of 82 % (after 1200 cycles, Figure
6.11). This highlights the advantage of interdigitated electrodes in the application of
electrically controlled drug delivery. [7].
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Figure 6.11 Comparison of the release amount from a single 3D electrode with
that from two interdigitated 3D electrodes.
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As shown in Figure 6.12, after 1200 cycles of electrical stimulations (pulsed waveform; -0.5
V for 5s, followed by 0.5 V for 5s), no obvious delamination or breakdown was observed on
the surface of the PPy coating, indicating good stability.

a

10 µm

b

1 µm

Figure 6.12 SEM images of the PPy fos-phenytoin coating after 1200 cycles of electrical
square wave, biphasic voltage stimulation (-0.5 V for 5s, followed by 0.5 V for 5s), no
obvious delamination or breakdown was observed on the surface of the PPy coating.
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6.3.6 Drug release study of 3D electrode coated with PLGA/dexamethasone
microspheres coating
The drug encapsulation efficiency and drug release were first investigated by using an
extraction method as previously reported [34]. For effective drug action, improving the drug
encapsulation efficiency is critical in drug carrier research [35].

The PLGA microspheres coating exhibit excellent drug encapsulation efficiency as high as
93.5±5.1 %. The ultra-high drug encapsulation efficiency can be attributed to fast
solidification rate and minimum drug loss during the PLGA microspheres coating fabrication
process. Since the dexamethasone is directly encapsulated in PLGA by electrospraying, the
drug loss through diffusion into other continuous liquid phase is eliminated [37].
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Figure 6.13 Cumulative release of PLGA dexamethasone microspheres coating in
aCSF (pH 7.4) at 37 ℃.
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The in vitro release profile of dexamethasone from the electrospray PLGA microspheres
coating is shown in Figure 6.13. It shows an initial burst, followed by a long period of
gradual slowing release over nearly two weeks for the PLGA microspheres coating. Besides
by diffusion through the polymer barrier, the dexamethasone release from the PLGA
microspheres coating also occurs by erosion of the microspheres, due to the hydrolytic
degradation of the ester linkages. This degradation leads to formation of interconnecting
pores and channels within the microspheres in the coating which would increase diffusion of
the dexamethasone into the aCSF solution. The rapid initial release was probably due to the
drug aggregation close to the surface of the PLGA microspheres in the coating [36]. Due to
the hydrophobic characteristics of dexamethasone, there is a tendency for it to migrate to the
surface during electrospraying. Whereas the latter gradual slow release maybe ascribed to
diffusion of the drug within the core of the PLGA microspheres coating.

For PPy, drug release can be switched on/off and accurately controlled by electrical
stimulation, while for PLGA microspheres coating, the release of dexamethasone is passive
and Fickian diffusion related. Previous studies have elucidated the complex phenomena that
are involved in the control of drug release from PLGA microspheres [24, 38, 39]. It has been
identified that the crucial drug release rate was controlled by a diffusion mechanism. For the
PLGA microspheres coating, the diffusion controlled release rate decreases with increasing
size of the microspheres coating. Size increase leads to slower drug release since the drug has
a further distance to diffuse to the surface of the microsphere. It’s important to apply a
mathematical model which takes into consideration the size and shape matters of the PLGA
microspheres [38].
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The mathematical model assumes uniform initial drug distribution in the microspheres and
constant drug diffusion coefficients. Based on this assumption and Fick’s second law, the
resulting drug release rate can be described by the following equation:

∞
M𝑡
𝑀∞

=1−∑

6

((𝑛𝜋)2 )𝑒

−

4(𝑛𝜋)2 𝐷𝑒 𝑡
𝑑2

(6.1)

𝑛=0

Where M𝑡 is the amount of drug release at time 𝑡, 𝑀∞ is the total amount drug release, 𝑑 is
the diameters of the microspheres in coating, 𝐷𝑒 is the effective diffusivity of the drug
(International system od units).
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Figure 6.14 Diameters distribution of the dexamethasone PLGA microspheres.
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The diameters ( 𝑑) were obtained by analysis of the SEM images of the PLGA microspheres
coating. The diameters are 3.97±0.44 µm, and the diameters distribution is shown in Figure
6.14. It shows that the as-fabricated microspheres coating have uniform morphology with a
narrow size distribution.
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Figure 6.15 Comparison of the mathematical modelling results with the
experimental drug release profiles of electrospray PLGA dexamethasone
microspheres coating.

The fitting method was based on the minimization of the differences between experimental
and theoretical results (least squares fitting method). The fitted results agree well with the
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experimental drug release rate (Figure 6.15). It’s consistent with previous studies, and the
drug release mechanism of the PLGA microspheres can be described as a time-dependent
diffusion controlled release [24, 38, 39]. The calculated effective diffusivity (𝐷𝑒 ) is 1.2×10-12
cm2/min, which is within the values range of hydrophobic drugs in a PLGA matrix [40].

a

10 µm

b

1 µm

Figure 6.16 SEM images of PLGA dexamethasone microspheres coating after more than
three months release incubation. It shows that the PLGA retained its spherical structure.
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We also conducted SEM observations on the PLGA microspheres coating after more than
three months of release. Figure 6.16 shows that the PLGA retained its spherical structure.
This confirms that the breakdown of the polymeric network does not occur during the whole
drug release period. Thus, it does not contribute to the control of the release process.

6.4 Conclusion
In summary, this work developed 3D drug delivery systems based on 3D printed electrodes.
After electropolymerization of a layer of PPy fos-phenytoin coating, the 3D electrodes
showed electrically controlled property, sustained near-linear release, flexible dosage control,
and super stability. The electrosprayed PLGA dexamethasone microspheres coated on the 3D
electrodes demonstrated uniform morphology and theoretically predictable release properties.
The combination of conducting and biodegradable polymers by these two interdigitated
electrodes can serve as multi-functional drug delivery systems. The electrical conductivity,
biocompatibility and controllable release of this 3D printed drug delivery system can lead to
promising localized treatment of central nervous system diseases such as epilepsy.
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7. CHAPTER 7: CONCLUSIONS AND
FUTURE WORK
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7.1 General Conclusion
The main aim of this study was to develop biocompatible controlled drug delivery systems
for treatment of central nervous system disorders such as epilepsy. Biodegradable polymer
and conducting polymer were used as carriers. The US Food and Drug Administration (FDA)
approved lacosamide, phenytoin and dexamethasone are used as model drugs. Electrojetting
and electropolymerization are used as fabrication methods.

The preparation and characterization of microcapsules including flattened microspheres,
microspheres, and microfibres are described in chapter 3. Electrojetting technology
(electrospraying and electrospinning) were used to fabricate these microcapsules containing
the anti-epilepsy drug, lacosamide. The SEM images and their statistical analysis results
showed uniform morphology and a narrow size distribution of the microcapsules. The drug
release study demonstrated high drug encapsulation efficiency, and that their drug release
profiles are dependent on the shape and size of the microcapsules. The mathematical
modelling studies demonstrated that all drug release profiles could be predicted, with a good
agreement between the modelling and experimental results. Human neural stem cell culture
results indicated the neuro-cytocompatibility of the microcapsules. It was confirmed by the
cell attachment and viability during extended cell culture with the microcapsules. These
findings broadly support the utility and efficacy of the local drug delivery systems for treating
human brain disorders such as epilepsy.
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After successful fabrication of the neuro-compatible microcapsules, the development of coreshell structural microcapsules using the same biodegradable polymer was investigated in
chapter 4. A series of core-shell microcapsules were prepared via novel core-shell
electrojetting, where a more hydrophobic polymer shell acts as a barrier component to control
the rate of drug release from the polymeric core. By adjusting the applied voltage and the
core and shell solution compositions, different kinds of microcapsules were successfully
obtained, including core/-shell microflakes, flattened microspheres and microspheres,
microspheres/fibres, microbeads/fibres, and microfibres. The release profile varies with the
morphologies and shape of the core-shell microcapsules and thus can be readily controlled
over long periods of time.

Many central nervous system disorders in clinical situations require more than mono drug
release. For example, combination therapy with drugs of different therapeutic effects
provides an effective strategy in the treatment of epilepsy. Electrospun microfibres and
electrosprayed microspheres composite membranes were prepared as dual drug delivery
systems in chapter 5. These composite membranes were loaded with two drugs, one in the
biodegradable microspheres and the other in the microfibres. The microspheres and
microfibres could form stable composite structures. Thermogravimetric analysis and tensile
testing results indicated favourable thermal and mechanical properties. Independently
controlled release behaviours are achieved in these dual drug delivery composite membranes.

In chapter 6, 3D printed interdigitated electrodes were used as drug delivery systems by a
combination of conducting polymer film and biodegradable polymer microspheres. The
interdigitated structure provided flexible drug delivery combination both for mono drug
213

delivery and dual drug delivery systems. The electrochemical impedance spectroscopy (EIS)
and cyclic voltammetry (CV) results showed the excellent electrochemical properties of the
3D electrodes. Conducting polymer coated electrodes demonstrated sustained near-linear
release. The release amount of drug could be controlled by altering the stimuli potential.
Assembling of two conducting polymer coated interdigitated electrodes significantly
increased the capacity of drug loading. The biodegradable polymer microspheres coated 3D
electrodes were also fabricated. By the assembling of microspheres coated electrode with the
conducting polymer coated electrode, interdigitated dual drug delivery systems were
developed.
In summary, a series of biodegradable microcapsules and 3D conducting polymer drug
delivery systems have been successfully developed in this thesis. All delivery systems
showed biocompatibility, controllable shape, size, and drug release properties. These novel
drug delivery systems demonstrate great potential application in the local treatment of central
nervous system (CNS) disorders such as epilepsy.

7.2 Future work

7.2.1 Electrojetting biodegradable microcapsules
Electrojetting has been a facile and simple technique for fabricating many kinds of
microcapsules including micro-particles and microfibres [1-3]. These microcapsules
demonstrated varied drug release profiles depending on their shape and size. The release
periods are from several days to several months. However, further increasing the release time
is still a huge challenge [4-6].
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The drug release time already has been extended to several months by using the core-shell
electrojetting technique. From the perspective of clinical applications, the longer release with
even kinetics over the duration of the implant would be best. In order to further prolong the
drug release duration, one promising method is to increase the shell/core ratio of the
microcapsules [5]. For the microcapsules, the drug release rate decreases with increasing size
of the microcapsules, as a result of increased diffusion distance.
Another approach is to add a more hydrophobic component as drug carrier [7]. The
hydrophobic component would prevent water penetration into the microcapsules. It will also
decrease the degradation of the polymer carrier leading to reduction of drug diffusion.

Two administrations would be applied to the delivery of electrojetting microparticles and
microfibres to a patient. Because the granular polymeric delivery systems could be
distributed in an injection solution, the microcapsules including microflakes, flattened
microspheres, and microspheres are suitable for injected administration. However, for the
fibrous polymeric delivery systems, which are gathered as fibre matrix, administration by
implanting should be considered.

For the electrospun microfibres and electrosprayed microspheres combined structure, it
would be worth undertaking more detailed investigations incorporating modelling based on
this new structure using a single drug.

Apart from drug delivery applications, electrojetting microparticles and microfibres could be
used in other biological areas such as cell culture and tissue engineering [6, 8]. Some
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biomacromolecules e.g. protein, DNA, and growth factor could be incorporated into the
biodegradable microcapsules for these related biomedical applications.

7.2.2 Electropolymerization of conducting polymer
3D printing is a novel technology for fabrication of complex, personalized products from
digital designs [9-11]. Since a 3D printed drug had been approved by the FDA recently, 3D
printing has attracted increasing interest in pharmaceutical fabrication [12]. In this study, 3D
printed interdigitated electrodes were used as drug delivery systems. This technique also can
be used to fabricate many other micro-structures. These structures can be designed to fulfil
clinical requirements. Furthermore, the surface of the printed electrodes also can be modified
by using conducting polymers and biodegradable polymers.
Carbon nanomaterials, such as carbon nanotube, graphene, and graphene oxide have received
tremendous attention in controlled drug delivery applications recently due to their large
surface area and sp2 carbon lattice [13-18]. Graphene oxide is composed of a honeycomb
carbon lattice structure with hydroxyl, carboxyl, and epoxide functional groups. The aromatic
drug compounds enable π-π interactions with graphene oxide by localized π-electrons [19].
Targeted drug delivery can be achieved by covalently modifying drug loaded graphene oxide.
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200 nm

5 µm

Figure 7.1 SEM images of PPy/graphene oxide/fosphenytoin coated on the surface of 3D
printed electrode.
Preliminary studies showed that the graphene oxide sheets could be incorporated into
conducting polymer (PPy) film (Figure 7.1). The conducting polymer and graphene oxide
could be co-deposited on the surface of the 3D printed microstructures. The as-fabricated
composite film shows promising possibilities for electrically controlled drug release
application.
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